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BACKGROUND: The goal of this dissertation was to create a risk phenotype which 
could be used to represent the intensity of injection drug use and to link this phenotype to 
genetics. In paper 1, a review of the literature suggests that a) injection drug users are at 
high risk for HIV and are at the highest risk for dependence among drug users, b) 
substance use disorders are chronic and recurrent, and c) genetic factors influence opioid, 
and other drug, addiction. In paper 2, I devised a risk phenotype, injection-years. In paper 
3, I conducted genome wide analysis using injection years as the risk phenotype. 
METHODS: Data for paper 2 and paper 3 came from the AIDS Linked to the 
Intravenous Experience (ALIVE) cohort. Paper 2 deals with the problem of missing data 
in a longitudinal data set, using three different imputation models and examining the 
sensitivity. Using the imputed ALIVE GWAS cohort I created the risk phenotype, termed 
“injection years”. In paper 3, I conducted three analyses: genome wide association 
analysis, polygenic risk score analysis, and pathway analysis to explore the association 
between injection years and genetics. 
RESULTS: Our results concerning injection years are consistent with Genberg’s 
findings, which used the same ALIVE cohort. This result suggested that injection years 
could be used as a tool to measure the intensity of injection behavior. In genome wide 
analysis, no significant single SNP or gene sets were found. The findings suggest that 
injection years are influenced by polygenes.    
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CONCLUSION: Using the appropriate model, multiple imputation can provide reliable 
information for longitudinal data. Efforts to identify injection drug users who are most 
likely to be “persistent users” and to identify related genes could help decrease the public 
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Chapter 1: Introduction 
1.1 Substance use disorders  
Substance use disorders (SUD) are chronic and recurrent; they affect personal 
health and wellbeing and cause significant losses in a nation’s economic productivity. 
(Ersche, Clark, London, Robbins, & Sahakian, 2006; Hansen, Oster, Edelsberg, Woody, 
& Sullivan, 2011) According to DSM-V, substance use disorder is characterized by four 
groups of symptoms: impaired control, social impairment, risky use, and pharmacological 
reactions. (American Psychiatric Association, 2013) The risk of developing a SUD may 
be partly due to heritable factors through underlying behavioral risk dimensions like 
impulsivity and risk taking. (Kreek, Nielsen, Butelman, & LaForge, 2005) 
Individuals can be addicted to any number of psychoactive substances, including 
legal drugs like nicotine and alcohol. Illicit drugs and their accompanying problems are 
found the world over. In 2009, an estimated 149 to 271 million people worldwide 
admitted to having used at least one illicit drug: of that group 15 to 39 million had used 
an opioid, amphetamine, or cocaine, and 11 to 21 million had used an injected drug. 
(Degenhardt & Hall, 2012) Opioid overdose and opioid dependence are potentially lethal; 
moreover, the injection of opioids, cocaine, or amphetamines is a substantial risk factor 
for transmission of HIV, hepatitis C, and hepatitis B. (Degenhardt & Hall, 2012) The 
2009 survey excluded several types of illicit drugs: 3,4-methylenedioxy- N-
methylamphetamine (MDMA, or ecstasy), hallucinogens, and inhalants, thus the actual 
number of illicit drug users  is likely even higher. According to the results from the 
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), the 12-
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month prevalence in the United States of substance use disorder was 9.35% and of any 
drug use disorder, 2.00%. The prevalence of opioid use disorder, amphetamine use 
disorder and cocaine use disorder was 0.35, 0.16, and 0.27, respectively.  (Grant et al., 
2004) A study by Monitoring the Future found that the number of users of injected heroin 
rose from 0.3% in 2009 to 0.7% in 2010. (Johnston, O’Malley, Bachman, & Schulenberg, 
2013) In addition to the impact on the individual drug user, there is a larger cost to 
society. In Western countries, alcohol abuse and drug addiction consume approximately 
3.5% of gross domestic product. (Pouletty, 2002) 
1.2 The human immunodeficiency virus (HIV) and 
acquired immunodeficiency syndrome (AIDS) 
Acquired immunodeficiency syndrome (AIDS) was first reported in 1981 in 
California and New York among a small group of homosexual men. (Center for Disease 
Control, 1981; Friedman-Kien et al., 1981) A classic symptom of AIDS is a complete 
loss of CD+4 (cluster of differentiation 4) T cells which leads to immune deficiency and 
an increased susceptibility to opportunistic infections and Kaposi’s sarcoma. In 1983 a 
retrovirus, now called the human immunodeficiency virus (HIV), was implicated as the 
cause of AIDS, and the transmission pathway was identified as bodily fluids: blood, 
semen, vaginal secretions and breast milk. Diagnostic tests were developed to identify the 
infection, which helped prevent its transmission; prevention programs emphasizing risk 
reduction, condom distribution, and needle exchange are now commonplace. 
Antiretroviral therapy (ART) is used to treat HIV, of which there are six types: a) 
nucleoside/nucleotide reverse transcriptase inhibitors, b) nonnucleoside reverse 
3 
 
transcriptase inhibitors, c) protease inhibitors, d) fusion inhibitors, e) CCR5 antagonists, 
and f) integrase inhibitors. (Panel on Antiretroviral Guidelines for Adults Adolescents, 
2009) Currently, highly active antiretroviral therapy (HAART), which combines at least 
three drugs from two classes of antiretroviral agents, has proven highly effective in 
slowing the progress of HIV/AIDS. However, the AIDS virus is highly mutable and drug 
resistance remains a possibility. Prevention remains the most effective means of   
reducing HIV transmission rates. 
HIV was first described in June 1981. Within a decade, the three main 
transmission routes were identified as via blood, sexual, and perinatal. The virus enters 
the bloodstream through transfusions with contaminated blood or blood products, needle 
sharing among injection drug users, and injections with unsterilized needles. Sexual 
transmission routes of the virus include homosexual contact between men and 
heterosexual contact from men to women or women to men. Perinatal transmission can 
occur intrauterine and peripartum. (Friedland & Klein, 1987) Because of the high 
prevalence of HIV/AIDS among injection drug users, many studies have focused on 
efforts to stop or slow its spread within this specific population.  
1.3 The AIDS Linked to the Intravenous Experience 
(ALIVE) cohort 
The AIDS Linked to the Intravenous Experience (ALIVE) is a longitudinal 
prospective community-based study of injection drug users in Baltimore. The ALIVE 
was established in 1988. It is one of the longest-running community-based cohorts of 
injection drug users. In its early years, the primary goal of the ALIVE study was to 
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understand the natural history of HIV in the population of IV drug users. Since 1998, the 
ALIVE study has expanded its focus on participants’ access to treatment for HIV and 
other non-AIDS outcomes including hepatitis C as well as the impact of this treatment. 
The annual rate for loss-follow-up is five percent; the death rate is two to three percent. 
The ALIVE study provides an excellent longitudinal sample for research on injection 
drug users. The ALIVE GWAS subsample, a set of 1197 subjects genotyped on the 
Affymetrix 6.0 GWAS chip, will be used for this proposed study. (Galai, Safaeian, 
Vlahov, Bolotin, & Celentano, 2003; Vlahov, Anthony, Muñoz, & Margolick, 1991)  
1.4 Personal hazard, social cost, and public health 
significance  
Different substances are associated with different diseases. Smokers experience 
high rates of lung cancer. Alcoholics suffer from cirrhosis of the liver. Illicit drugs--
psychoactive drugs--are associated with a variety of psychological problems, chief 
among them the high risk of addiction. The signs and symptoms most commonly 
associated with drug addiction are euphoria, tolerance and withdrawal. (Wise & Bozarth, 
1984) One class of highly addictive drug is the opioids. Opioid addiction inflicts damage 
at all levels of society.  Opioids are frequently injected in order to bring on a faster 
euphoric rush. When drugs are injected, users run the risk of acquiring infectious diseases. 
(Vlahov et al., 1998) Another consequence of continuous opioid and amphetamine use is 
functional impairment, in particular cognitive impairment and poor judgment. (Ersche et 
al., 2006) Lapses in judgment result in risky or dangerous behavior to oneself or others. 
Furthermore, the cost of the drugs combined with the constant need to assuage the 
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craving lead addicts to engage in high-risk, often illegal activities that result in run-ins 
with the police and involvement in the judicial system. (Rounsaville & Kleber, 1985; 
Rounsaville, Tierney, Crits-Christoph, Weissman, & Kleber, 1982) 
Just as society must pay the price for its addiction to alcohol and tobacco, there is 
also an enormous societal cost to opioid addiction in the United States. (Birnbaum et al., 
2011) First, there is the cost to the health care system. Medical spending on individuals 
with addiction (who not only have comorbid psychiatric disorders but may also have 
diseases like HIV/AIDS) costs the U.S. nearly $1 billion a year. (Hansen et al., 2011) 
Second, there is the cost to the American economy:  the U.S. loses $42 billion a year in 
workplace productivity because of this problem. (Hansen et al., 2011) Finally, there is the 
cost on the criminal justice system; annually, this costs the U.S. $8.2 billion. (Hansen et 
al., 2011)  
Substance use disorders are chronic and recurrent. Early intervention may be the 
best way to treat patients with complicated clinical conditions. Injection drug users have 
high rates of HIV; it is therefore critical to identify those who are at higher risk of 
developing HIV risk behaviors for the purposes of early intervention. It is hoped that the 
findings from this study may help with clinical and policy efforts to understand the 
mechanisms of injection patterns, to provide prediction tools, and to connect brain 
biology to behavior patterns. Further, it is hoped that these findings may contribute to 
efforts at secondary prevention defined here as the reduction of the impact of a disease or 




1.5 Complex genetic etiology 
Genetic epidemiology is a rapidly expanding field of research; it uses a powerful 
set of tools that helps find answers to questions of etiology. (Burton, Tobin, & Hopper, 
2005) In recent decades, the results of classical genetic research using family studies, 
twin studies, and adoption studies support the premise that psychiatric disorders are not 
only environmental but also at least partly heritable. These include schizophrenia, bipolar 
I disorder, substance use disorders and others. (Hopper, Bishop, & Easton, 2005; Shih, 
Belmonte, & Zandi, 2004) Unlike psychiatric disorders such as anxiety, genetics plays a 
much more important role in substance use disorders. (Hettema, Prescott, Myers, Neale, 
& Kendler, 2005) The relative impact of genes and environment varies depending on 
stage of drug use. As drug use transitions from initiation, to continued use and then 
dependence, the relative impact of genes increases. (Tsuang et al., 1999; Wray, 2007) 
Furthermore, it is now easier and faster to perform large computational analyses such as 
genome wide association studies because of huge advances in computer technology. (Ott, 
1974) The discovery of the genetic underpinnings of psychiatric disorders has led to a 
surge in research using molecular analyses to identify and locate associated genes. 
Linkage studies, genetic association studies, genome wide association studies and, more 
recently whole genome sequencing, have become the norm. (Ozaki et al., 2002; Risch & 
Merikangas, 1996) The achievements of genetic epidemiology are widely apparent; 
nevertheless, challenges remain. This paper will focus on opioid addiction, one type of 
substance use disorder, and describe it in detail.  
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1.6 Guiding principals 
1.6.1 Longitudinal data analysis 
Substance use disorders are chronic and recurrent. Impulse control, which is a 
predisposition to and/or a consequence of substance use disorders, is also a core 
behavioral domain underlying many HIV risk behaviors. Unlike some HIV risk behaviors 
such as engaging in unprotected sex, substance use disorders are more proximally 
associated with brain biology. In order to study HIV risk behaviors among injection drug 
users, we will use the data in a longitudinal manner rather than reducing the data to a 
cross-section or single measure (e.g., lifetime dependence). The reason is that a 
longitudinal data provides more valuable information about the long-term trajectories of 
the HIV risk behaviors of injection drug users. This information may yield a phenotype 
that reflects severity and intensity in a way that is more strongly related to the underlying 
biology of the trait. Using longitudinal ALIVE injection data, we borrow the concept of 
“pack-years” to create our phenotype, injection years, (Caporaso et al., 2009) and analyze 
the composite HIV risk phenotypes of the trajectories of the participants. (Smith et al., 
2015) The lives and relationships of injection drug users tend toward instability; hence, 
there exists virtually no perfect attendance record for any single participant in this study. 
For this thesis, we accessed the ALIVE cohort, a longitudinal community-based study, 
and we use statistical approaches to impute the missing data. Furthermore, the analysis 




1.6.2 Sub-population and sub-phenotypes analysis  
The ALIVE cohort is a longitudinal community-based study of injection drug 
users, primarily African Americans, in Baltimore. This urban minority population is at 
high risk of illicit drug use and dependence (Reuter, Hsu, Petronis, & Wish, 1998) and 
there is scant research on the association between their genetic makeup and HIV risk 
behaviors, including drug injection. We believe that our results may enhance prevention 
and treatment strategies and aid in identifying subpopulations at high risk of persistent 
drug use. In addition, it may be possible to identify a composite of HIV risk behaviors 
that are more amenable to prevention strategies. In addition, in studying this targeted 
population we avoid a very common pitfall of genome wide association analyses: the use 
of samples from different geographical regions with individuals of different genetic 
backgrounds.   
Genome wide association studies (GWAS) are a major advance in the field of 
genetics yet there are limitations. First, GWAS cannot be applied to a select number of 
disorders which have very low genotypic risks or are influenced by only several rare 
SNPs. Second, current diagnostic categories might not reflect the heritability of a 
particular disorder. Third, gene-gene or gene-environment interactions are also factors.  
(Psychiatric GWAS Consortium Coordinating Committee, 2009) Borrowing the concept 
of “smoking-years”, we create several sub-phenotypes including injection years and the 
trajectories of composite HIV risk phenotypes. We believe that these phenotypes may be 
partly genetic in origin. It is hoped that these results will elucidate our understanding of 
modifiable and fixed components of HIV risk behaviors in this population, and lead to 




The genetic underpinnings of substance use disorders are frequently studied. 
Classic genetic approaches such as twin, family and adoption studies show that there are 
significant genetic influences on drug addiction.  Heritability is the proportion of 
observed differences on a phenotypic trait among individuals of a population that are due 
to genetic differences, and the heritability of addiction is estimated at 0.4-0.6. (Kendler, 
Prescott, Myers, & Neale, 2003; Tsuang et al., 1998) In recent years, huge advances in 
computer technology have made molecular genetic approaches possible. Linkage studies, 
genetic association studies, and genome wide association studies can identify and locate 
associated genes. There have now been a number of studies on addiction behaviors using 
molecular approaches. (Cornelis et al., 2011; Crabb, Edenberg, Bosron, & Li, 1989; 
Sulem et al., 2011; Tobacco and Genetics Consortium, 2010; P. Xie et al., 2011)  
 Classical genetic approaches have shown that addiction is heritable; molecular 
genetic approaches suggest that specific addiction-related behaviors are associated with 
specific genes.  Herein, we create a phenotype from the ALIVE dataset: injection years. 
We believe that injection years and the trajectories of HIV risk behaviors are genetically 
influenced and we therefore use them as phenotypes in genome wide association analysis. 
Using the results from the genome wide association analysis, we conduct a pathway 
analysis and a polygenic risk score analysis. The pathway analysis yields information on 
the biological mechanisms of injection behavior patterns. The polygenic risk score 
analysis predicts injection behaviors. In brief, we analyze the association between 
behavioral phenotypes and genetic markers across the entire genome. Using identified 
genetic markers, the results may link behavioral phenotypes to the biological mechanisms 
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of addiction, either through the genome-wide significant association of single SNPs in 
relevant genes or through the overrepresentation of SNPs in specific biological pathways 
among the set of SNPs below some p-value. 
1.7 Chapter introductions 
 This dissertation is divided into five chapters. In the first chapter, I provide 
background information on addiction, HIV risk behaviors, genetics and emphasize public 
health significance. The ALIVE cohort and genetic etiology are introduced briefly in this 
chapter. There were three key elements of this dissertation: imputing before analyzing 
longitudinal data, creating a unique behavior pattern as a risk phenotype in a specific 
population, and using that behavior phenotype in genome wide analysis.   
 The second chapter is a review of the literature. The findings from the literature 
review support our proposition that injection drug users are at high risk of HIV infection, 
and injection behavior is highly associated with addiction, which is partly heritable. 
These findings suggest that creating a tool to measure the intensity of injection behavior 
is urgent from both a public health and personal health perspective, and using genome 
wide analysis on injection years may provide useful information. 
 Building on the findings in the second chapter, the third chapter describes the risk 
phenotype, injection years. I describe the importance of longitudinal data, compared to 
cross sectional data, and the most significant challenge, vast amounts of missing data. In 
order to solve this problem, I used three different models to impute the entire dataset and 
conducted sensitivity exams for these three models. The findings pointed to using the 
universal imputation, a model which jointly imputes the entire panel of data, to create the 
injection years phenotype.  
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 The fourth chapter is an extension of the third chapter. Injection years, which was 
created from the imputed data, was used as a risk phenotype in genome wide association 
analysis, polygenic risk score analysis, and pathway analysis. By using different genomic 
analyses, I explored the association between injection years and single SNP as well as a 
group of SNPs with p-values below an arbitrary threshold, and a gene set of SNPs with a 
shared biological pathway. 
 The fifth chapter is a discussion and summary of the results. The findings of this 
dissertation support our proposition that multiple imputation can address the issue of 
large amounts of missing data in a longitudinal dataset and using injection years to 
evaluate the intensity of injection behavior is possible. The genetic findings suggest that 
injection years is influenced by polygenes. In conclusion, I believe that linking genetic 
studies to observable behaviors, particularly behavioral trends in a longitudinal dataset, 
can provide valuable information about how genetic factors influence individuals’ 










Chapter 2:  A review of the evidence suggesting 
specific behavior patterns such as the use of 
injection drugs are related to genetic factors 
 
2.1 Abstract 
Injection drug use is a common administration route of substance use disorder. 
The use of drugs like heroin increases the risk of HIV. Studies have found the use of 
alcohol, tobacco, marijuana, opioids, and stimulants are prevalent among people with 
HIV. In particular, heavy drink is very common among people in care for HIV infection. 
Studies from a number of different countries have found that thirty-one to eighty-four 
percent of HIV+ individuals are smokers. The use of stimulants like amphetamines and 
cocaine is widespread among HIV positive injection drug users.  
Using Diagnostic and Statistical Manual of Mental Disorders 4th edition, 
substance-related disorders include substance use disorders or substance-induced 
disorders. It lists several classes of substances: alcohol, amphetamines,  cocaine, nicotine, 
and opioids. The symptoms and signs including tolerance, withdrawal, increasing 
uncontrolled intake, spending more time and money on substances, and impaired social, 
occupational, or recreational function are observed as part of the diagnosis of substance 
dependence. This complex of symptoms and signs can be categorized into four 
dimensions: impaired control, social impairment, risky use, and physiological reactions 
caused by the substance. 
 Since the 1960’s with the first twin studies of alcoholism it has been posited that 
there is a genetic component to addiction. Scientists are now using molecular approaches 
in genetic epidemiology to identify the location of addiction-associated genes.  
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In this thesis, a new phenotype has been created: injection years. We imputed 
each participant’s biannual injection behavior to address the issue of missing information 
and then took the sum of his or her injection behavior to create an “injection years” 
phenotype, considering it as a continuous variable. We then performed a descriptive data 
analysis. Borrowing the concept of smoking pack-years, we believe that the injection 
years trait is associated with genetic factors. Furthermore, assuming that multiple genes 
with small effects contribute to injection years, we performed a polygenic risk score 
analysis and pathway analysis to attempt to ascertain which biological pathways are 
related to this variable.  
2.2 A review of the literature on substance use disorders 
and HIV 
The use of illegal and injectable drugs like heroin increases the risk of HIV. There 
are three main transmission routes: contaminated blood, sexual contact, and perinatal 
exposure. Contaminated blood comes from transfusions of blood and blood products, 
needle sharing among injection drug users, and injection with unsterilized needles. 
(Friedland & Klein, 1987) Injection drug users are at high risk of becoming HIV-infected 
regardless of age early detection and advances in treatment make it possible for HIV 
positive individuals to live longer. The population of HIV-positive patients, in particular 
those with substance use disorders, is aging. This is a rather serious public health issue 
and has led to a number of studies on the subject. Edelman et al. reviewed articles related 
to substance use in older HIV-infected patients and found that the situation of substance 
use in the older population remains severe. (Edelman, Tetrault, & Fiellin, 2014) Pilowsky 
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et al. reviewed the articles related to risky behaviors among older HIV-infected patients 
and he found that substance use increased the risk for HIV risk behaviors and the 
prevalence of substance use disorder is increasing among the elders in the past decades; 
thus, older Americans may be at increased risk for HIV infection.  (Pilowsky & Wu, 2015) 
The number of Americans at 65 years or older with substance use disorder is rising 
because the population is aging and life expectancy is increasing. (Lofwall, Brooner, 
Bigelow, Kindbom, & Strain, 2005; Rosen, Smith, & Reynolds, 2008; Wu & Blazer, 
2014) Although injection drug users are at high risk of HIV regardless of age, this 
specific population in the United States is also aging. Armstrong et al. estimated that in 
the United States, the mean age of injection drug users increased from 26 to 42 between 
1979 and 2002. (Armstrong, 2007) The longer injection drug users live, the higher the 
prevalence of HIV infection in that population. 
The use of alcohol, tobacco, marijuana, opioids, and stimulants is prevalent 
among those infected with HIV. There are four types of unhealthy alcohol use: risky 
drinking, problem drinking, harmful use or alcohol abuse, and alcoholism or alcohol 
dependence. (Saitz, 2005) Heavy drinking (equal to or more than 5 drinks over 1 to 4 
days) is common among people in care for HIV infection. (Burnam et al., 2001; Galvan 
et al., 2002) Among the HIV positive population, the prevalence of alcohol use disorders 
is estimated to range from 29% to 60%. (Petry, 1999) Studies of HIV positive people 
from many different countries show that thirty-one to eighty-four percent of HIV positive 
individuals are smokers. (Brennan, 2012) HIV positive participants report that  in spite of 
the negative health effects and the cost of cigarettes, they felt more relaxed and better 
able to manage  anxiety, anger and depression by using cigarettes. (Shuter, Bernstein, & 
15 
 
Moadel, 2012) In the same study, alarmingly, 27% of the participants believed that 
smoking would help increase white blood cell counts. (Shuter et al., 2012) Marijuana is 
also used to self-medicate physical and emotional problems. Prentiss et al. found that 
HIV positive individuals reported that using marijuana improved their mood and appetite 
and decreased anxiety, nausea and pain; (Prentiss, Power, Balmas, Tzuang, & Israelski, 
2004) they also found that using marijuana  improved adherence to medication treatments 
by decreasing feelings of nausea.  (de Jong, Prentiss, McFarland, Machekano, & Israelski, 
2005) Injection drug users are at high risk for HIV, with heroin the most commonly 
injected drug. The use of stimulants like amphetamines and cocaine is widespread among 
HIV positive injection drug users specifically among homosexual men. In Skeer et al.’s 
study, 20.7% of subjects reported using methamphetamine and crystal methamphetamine, 
and 17% reported the use of cocaine. (Skeer et al., 2012) From 2005 to 2010, Mimiaga et 
al. followed a group of HIV positive individuals in the United States and found that nine 
percent reported amphetamine use and another nine percent reported crack–cocaine use. 
(Mimiaga et al., 2013) 
2.3 A literature review of genetic epidemiology and 
substance use disorders  
2.3.1 Substance use disorders 
DSM-IV classifies substance-related disorders in two ways: substance use 
disorders and substance-induced disorders. There are eleven classes of substances: 
alcohol, amphetamines, caffeine, cannabis, cocaine, hallucinogens, inhalants, nicotine, 
opioids, phencyclidine, and sedatives, hypnotics, or anxiolytics. Substance use disorders 
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are further identified as either substance abuse disorder or substance dependence disorder. 
Substance-induced disorders are categorized as substance intoxication, substance 
withdrawal, and substance-induced mental disorders. The criteria for diagnosing 
substance dependence include tolerance, withdrawal, increasing of uncontrolled intake, 
spending more time and money on substance, and impaired social, occupational, or 
recreational function. The criteria which must be met to make a diagnosis of substance 
abuse include primarily recurrent substance use resulting in legal problems, physical 
hazard, and failure to fulfill work, social, or home roles. In contrast, the criteria necessary 
for defining substance dependence relate to physical changes, behavioral changes, and 
significant loss of function. (American Psychiatric Association, 2000) 
In 2013, DSM-V revised the criteria for defining and diagnosing substance-
related disorders. The most significant change is that substance abuse disorder and 
substance dependence disorder are seen as one category: substance use disorder. In DSM-
V, “substance use disorder” includes most of the criteria for “substance dependence 
disorder” and “substance abuse disorder” from DSM-IV; DSM-V no longer mentions the 
criterion of “recurrent substance use resulting in legal problems” while adding the 
criterion of “craving to use substance.” Furthermore, DSM-V’s criteria for making a 
diagnosis of substance use disorder can also be used to indicate its current severity.  A 
diagnosis of “mild” indicates the presence of two or three symptoms, “moderate” means 
the presence of four or five symptoms, and “severe” is the presence of six or more 
symptoms. (American Psychiatric Association, 2013) 
   This change between DSM-IV and DSM-V in the view of substance-related 
disorders reflects the shift from a categorical view to a dimensional approach. A 
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categorical view is used by clinicians to meet the needs for reporting to health care 
planners and insurance companies, whereas a dimensional approach conceptualizes a 
quantitative disorder that is more useful for the purpose of research. (Saunders, Schuckit, 
Sirovatka, & Regier, 2008) 
2.3.2 Symptoms and signs of substance use  
Substance use disorder is a complex of symptoms and signs that involve the 
domains of cognition, behavior, and physiology. The persistent use of a substance can 
induce changes in brain circuits and cause specific behavior patterns such as craving. 
According to DSM-V, substance use disorder has four dimensions: impaired control, 
social impairment, risky use, and physiological reactions caused by substances. Impaired 
control includes taking larger amounts than intended, multiple unsuccessful efforts to 
decrease or discontinue use, spending a great deal of time on the substance, and craving. 
Social impairment refers to family, occupational, or other social problems.  Using 
substances in a physically hazardous situation and/or using substances despite the 
knowledge of its consequent physical or psychological problems define the category of 
risky use.  
Physiological effects of a substance include tolerance and withdrawal symptoms. 
Impaired control and risky use are the symptoms and signs resulting from behavioral 
changes which occurred with persistent use. Social impairment refers to the consequences 
of persistent use. (American Psychiatric Association, 2013) 
2.3.3 Approaches to the study of genetic epidemiology 
Since the 1950s, technological advances have changed the field of genetic 
epidemiology. Genetic epidemiology has become a fundamental clinical practice; family 
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history is a basic diagnostic tool for many inherited diseases. (Thompson, Orvaschel, 
Prusoff, & Kidd, 1982) In 1955, Morton et al. demonstrated how the logarithm of odds 
scores could be used to detect linkage. (Newton E Morton, 1955) In 1974, Ott and 
colleagues began using a computer program to conduct linkage analysis. (Ott, 1974) In 
1996, an association map was developed for complex diseases. (Risch & Merikangas, 
1996) In 2002, Ozaki and his colleagues published the first genome wide association 
study (GWAS) using SNP markers. (Ozaki et al., 2002) In 2007, the Psychiatric GWAS 
Consortium began to conduct meta-analyses of genome-wide association studies for five 
psychiatric disorders: autism, attention-deficit hyperactivity disorder, bipolar disorder, 
major depressive disorder, and schizophrenia.(Sullivan, 2010) In 2009, the International 
Schizophrenia Consortium developed an innovative approach to evaluating the risk of 
schizophrenia and bipolar disorder: the polygenic score. (Purcell et al., 2009)  
2.3.3.1 Classic and molecular genetic approaches 
 The purpose of genetic epidemiology is to understand how genetic factors 
influence health and disease in families and in populations and to interpret the 
interactions between genetic and environmental factors. Morton defined genetic 
epidemiology as "a science which deals with the etiology, distribution, and control of 
disease in groups of relatives and with inherited causes of disease in populations". 
(Newton Ennis Morton, 1982) Genetic epidemiology attempts to answer two questions: Is 
the disease influenced by a genetic component? If the answer is yes, what genes are 
involved and where are they? Several different types of studies have been designed to 
answer these questions, twin studies, adoption studies, and family aggregation studies 
answer the first question, “Is disease X influenced by a genetic component, and if so, 
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what are the relative contributions of genes and environment?” Segregation studies help 
to find patterns of inheritance of disease. Linkage studies help to determine which part of 
which chromosome the disease is associated with. Finally, association studies identify 
which allele of which gene the disease is associated with. (Williams, Carson, Passmore, 
Silvestri, & Craig, 2011) 
2.3.4 The genetic epidemiology of substance use disorders 
 As stated in chapter one, genetic epidemiology is a rapidly expanding field of 
research. (Burton et al., 2005) Both classical genetic research using family studies, twin 
studies, adoption studies, and molecular genetic research using linkage studies, genetic 
association studies, and genome wide association studies provide valuable information 
related to substance use disorders. This section provides a review of the latest genetic 
research on disorders involving tobacco, alcohol, and opiates. The subsequent section 
will discuss the possible genetic links between opioid use disorders and specific behavior 
patterns. 
 Kreek et al.’s review of the research on genes and addiction offered a three-
domain model that included genetics, diverse environmental factors, and drug-induced 
effects. (Figure 1)  (Kreek, Nielsen, & LaForge, 2004) In 1960, Kaij et al. conducted the 
first study of alcoholism in twins and in 1966, Partanen et al. conducted a similar twin 
study which further explored the associations between intelligence, personality, and 
alcohol consumption. These were the earliest studies proposing that specific addictions 
were heritable, or influenced by genes. (Kaij & Rosenthal, 1961; Partanen, Bruun, & 
Markkanen, 1966) An adoption study by Cloninger et al. concluded that genes influence 
alcohol abuse since adopted away probands had a greater resemblance to their biological 
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relatives than their adoptive family. (Cloninger, Bohman, & Sigvardsson, 1981) 
Furthermore, Cloninger et al.’s adoption study provided a classic approach to disentangle 
the influence of genetics from that of environmental factors. (Cloninger et al., 1981) In 
1988, Merikangas et al. reported an eight-fold increase in the odds of drug disorders 
among the relatives of probands with drug disorders, with the greatest odds ratio 
observed for addiction to the same substance. (Merikangas et al., 1998) Tsuang’s twin 
study posited that both environment and genes influence a person’s susceptibility to drug 
abuse; Tsuang also found that all commonly abused drugs--opiates, marijuana, sedatives, 
psychedelics, and stimulants--had an overall genetic variance from 0.3 to 0.5. Heroin had 
the greatest overall genetic variance, 0.54, and a shared genetic variance, 0.2, with other 
drugs. However, most of these drugs only have a low variance for specific genetic factors 
and only heroin had the greatest specific genetic variance at 0.4, indicating there could be 
unique genetic factors affecting opioid abuse. (Tsuang et al., 1998) Kendler and 
colleagues, in their seminal twin study on substance use disorders, found that lifetime 
drug use of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates had a 
range of additive genetic variance, or heritability, of 0.3 to 0.5. (Kendler, Jacobson, 
Prescott, & Neale, 2003) From twin studies to adoption studies, from alcohol to other 
substances, these classic genetic studies provide solid evidence that genetics plays an 
important role in substance use disorders. Subsequently, molecular genetic studies are 
exploring heritability on a deeper level. In the past twenty years, with huge advances in 
computer technology and genomic array technology, molecular genetic approaches are 
identifying or locating specific associated genes.  
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2.3.4.1 Heritability: nicotine addiction 
 Many studies have been conducted on the use of alcohol and tobacco. A large 
number of twin studies have reported significant heritability for tobacco addiction in 
different populations, regardless of sex or age. (Carmelli, Swan, Robinette, & Fabsitz, 
1992; A. Heath, Kirk, Meyer, & Martin, 1999; A. C. Heath, Madden, Slutske, & Martin, 
1995; Kendler, Thornton, & Pedersen, 2000; Koopmans, Slutske, Heath, Neale, & 
Boomsma, 1999) Mcgue et al., in a twin study, found that the heritability of tobacco use 
and nicotine dependence was 40% to 60%. (McGue, Elkins, & Iacono, 2000) ) A family 
study by Cheng et al. identified a major segregating factor for “ever-smoking”, or 
lifetime cigarette smoking. (Cheng, Swan, & Carmelli, 2000) With data from families in 
the Collaborative Study on the Genetics of Alcoholism (COGA), some linkage studies 
have reported that several specific chromosome sections are associated with smoking 
behaviors. Bergen et al. reported some linkage between smoking behaviors and 
chromosomes 6, 9 and 19. Additionally, linkage existed between several candidate gene 
regions and smoking pack-year history. (A. W. Bergen, Korczak, Weissbecker, & 
Goldstein, 1999) Duggirala et al. also found linkage between smoking pack-year history 
and a genetic region on chromosome 5q, suggesting that a variant or variants near this 
marker (D5S1354) on chromosome 5q might be the primary determinant of genetic 
variation in smoking. (Duggirala, Almasy, & Blangero, 1999) This site is also close to the 
locus for dopamine receptor D1 which is associated with smoking. (Comings et al., 1997) 
Thorgeirsson et al. conducted a GWAS for nicotine dependence and smoking 
behavior. They found that nicotine dependence and cigarettes per day are associated with 
rs1051730 which is associated with the nicotinic acetylcholine receptor gene cluster on 
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chromosome 15q24. (Thorgeirsson et al., 2008) The Tobacco and Genetics Consortium 
conducted GWAS meta-analyses to examine four smoking phenotypes: smoking 
initiation, age of smoking initiation, smoking quantity or number of cigarettes smoked 
per day (CPD) and smoking cessation. (Tobacco and Genetics Consortium, 2010) They 
found that three loci are associated with CPD and the top most strongly associated SNP is 
rs1051730, which is in linkage disequilibrium with the nicotinic receptor gene CHRNA3.  
2.3.4.2 Heritability: alcohol addiction 
 Alcohol addiction is partly heritable. Two twin studies estimate the heritability of 
alcohol addiction at 48% to 58% for males and 51% to 59% for females. (Kendler, Neale, 
Heath, Kessler, & Eaves, 1994; Prescott & Kendler, 1999) Due to the nearly ubiquitous 
exposure to the substance, alcohol offers a unique way of understanding the probability 
of/susceptibility to addiction since all “controls”, or non-dependent individuals, are likely 
to have been exposed. In 1989, the COGA began to identify genes implicated in 
alcoholism. (Edenberg, 2002) Investigators in the COGA study refined the definition of  
alcoholism beyond that in the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IIIR).Using a family-based linkage study design, they found that drug and/or 
alcohol dependence are associated with a handful of identified “regions of interest” on 
human chromosomes 1, 2, 3, 4, 7, and 11. (Foroud et al., 2000; Long et al., 1998; T. 
Reich et al., 1998; Stallings et al., 2003) In the same way that certain genes make people 
more susceptible to addiction, other genes seem to make people less susceptible. Clinical 
observations of Asians with different phenotypes in metabolizing alcohol were the 
earliest studies on the genetics of vulnerability to addiction. Many Asians of the same 
ethnic descent exhibit a distinct facial flushing and experience severe hangover effects 
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after consuming alcohol. As a result, many Asians in this population have an aversion to 
alcohol. Consequently, the biochemical and genetic basis for the facial flushing 
phenotype in Asians was determined to be due to deficiencies in enzymes responsible for 
the breakdown and metabolism of alcohol. Several genes that are associated with a 
susceptibility to alcohol abuse are involved in the metabolism of alcohol. Of great interest 
is the gene for alcohol dehydrogenase (ADH), the enzyme which initiates the 
biochemical process of converting ethanol to acetaldehyde. ADH genes, which are linked 
to alcohol dependence, have been located on chromosomes 4q. (Long et al., 1998; 
Saccone et al., 2000; Van Eerdewegh et al., 1998) Another gene that has been linked to 
alcohol dependence is aldehyde dehydrogenase (ALDH) in liver mitochondria, a 
tetrameric enzyme that converts acetaldehyde to acetyl-CoA. In one study, individuals 
with inactive ALDH alleles accumulated high levels of acetaldehyde after consuming 
alcohol, which resulted in facial flush and severe hangover. (Mizoi et al., 1983) ALDH 
genes protect people of Asian lineage from developing problems with alcohol. (Harada, 
Agarwal, Goedde, Tagaki, & Ishikawa, 1982; Muramatsu et al., 1995) In brief, this is 
because the ADH genes are associated with faster metabolism of ethanol, causing 
acetaldehyde production and accumulation. The ALDH genes are associated with 
acetaldehyde metabolism, causing its accumulation. The interaction of ADH and ALDH 
genes contributes to painful hangover and thus appears to lessen the likelihood of 




2.3.5 The highest heritability: opioid addiction 
 Tsuang et al.’s twin study found that heroin had the greatest overall genetic 
variance, 0.54, and a shared genetic variance, 0.2, with all drugs. (Tsuang et al., 1998) 
Wilen and colleagues’ study of families in which parents were opioid-or alcohol-
dependent reported that children of addicts experienced higher rates of psychopathology 
including mood, anxiety, and substance use disorders. (Wilens et al., 2002) An adoption 
study by Cadoret et al found that heritable biological and environmental factors 
correlated with substance use. These results are consistent with twin studies. (Cadoret, 
Troughton, O'Gorman, & Heywood, 1986) 
 Scientists are now using molecular approaches in genetic epidemiology to identify 
the location of addiction-associated genes. Linkage studies are family-based studies that 
link to specific regions of the genome rather than a particular gene; they target 
phenotypes such as physical traits or specific diseases. (Teare & Barrett, 2005) Until 
twenty years ago, linkage studies could detect only a limited number of candidate genes 
because the technology was not sufficiently advanced; now, with much more powerful 
computers, genome-wide linkage studies are possible. Gelernter et al conducted a 
genome-wide linkage scan for opioid dependence and found that chromosomes 2 and 17 
are associated with opioid dependence. (Gelernter et al., 2006) Lachman and colleagues 
conducted another genome-wide linkage study of opioid dependence and found that a 
specific region of chromosome 14q is associated with opioid dependence. (Lachman et al., 
2007) Genome-wide association studies examine in an hypothesis-free approach that 
single SNPs throughout the genome are associated with a specific phenotype by 
comparing the affected individuals to non-affected individuals.(Psychiatric GWAS 
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Consortium Coordinating Committee, 2009; W. Y. Wang, Barratt, Clayton, & Todd, 
2005) Wetherill et al. conducted a genome-wide association study examining the 
association between candidate genes and substance dependence and found that one 
single-nucleotide polymorphism (SNP), rs2952621 in the uncharacterized gene 
LOC151121 on chromosome 2 and another SNP, rs2567261 in ARHGAP28 (Rho 
GTPase-activating protein 28), are associated with substance dependence. (Wetherill et 
al., 2015) In a separate genome-wide associations study Gelernter and colleagues found 
that SNPs from multiple loci-KCNG2*rs62103177 which involved potassium signaling 
pathways were associated with opioid dependence. (Gelernter et al., 2014) 
 Some behavior patterns such as impulsivity, risk taking and stress response, 
which are due to specific personality and physiological traits may make some people 
more prone to addictive disorders. These patterns may be partially influenced by genetic 
variation. Moreover, differences in personality and physiological traits may affect 
different stages of addiction. These stages of addiction are chronologically defined as 
initiation of drug use, regular drug use, abuse/dependence and relapsed use. (Kreek et al., 
2005) Clearly, many genes have been found to be associated with addiction. The focus of 
this work is on genes associated with heroin addiction. These genes can be classified into 
two gene systems: the dopaminergic system and the mu opioid receptor systems. (Kreek 
et al., 2004) Several single-nucleotide polymorphisms in the dopaminergic system are 
associated with heroin addiction. They include rs4680, rs1800497, rs1800955, rs1611115, 
rs1079597, rs747302, rs1800498, and rs936462. (Hou & Li, 2009; Vereczkei et al., 2013; 
X. Xie et al., 2013) ) The dopamine D4 receptor gene was also found to be associated 
with novelty-seeking, which is further associated with risk-taking. (Lusher, Chandler, & 
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Ball, 2001; Schinka, Letsch, & Crawford, 2002) Candidate genes OPRM1, rs1799971, 
rs7997012, and rs540825 in the mu opioid receptors system are associated with opioid 
dependence. (A. Bergen et al., 1996; Garriock et al., 2010; Haerian & Haerian, 2013) 
Table 1 lists characteristics of genes related to heroin/opiate dependence, including 
protein product, system, location on chromosome, and associated SNP. 
 Taken together, given the evidence for highest heritability in opioid and cocaine 
dependence plus lone successes in alcohol and tobacco are for use variation among users 
(metabolic) I conclude that studying use variation in opioid using subjects would likely 
yield success. 
2.4 Discussion: the link between the genetics of opioid 
addiction and specific HIV risk behaviors  
The goal of this paper was to review the literature related to substance use 
disorders, HIV risk behaviors, and genetics. Previous findings supported that substance 
use disorders are chronic. Injection drug use, one of HIV risk behaviors, is very common 
among population with substance use disorders, so they are at high risk of HIV infection. 
To study the trajectories of injected drug use is definitely important for HIV prevention. 
Furthermore, the most frequently injection use drugs are heroin and cocaine which had 
the greatest heritability. (Goldman, Oroszi, & Ducci, 2005) The successes in finding 
genetic factors of alcohol and tobacco use variation would argue that studying use 
variation in opioid using subjects would likely yield success.  
In the following chapters, a new phenotype --injection years-- has been created. I 
imputed each participant’s injection years to address the issue of missing information and 
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then took the sum of his or her injection years, considering it a continuous variable. I then 
performed a descriptive data analysis. Borrowing the concept of smoking pack-years, I 
believe that injection years will provide a more meaningful phenotype that is more ikely 
to be associated with genetic factors. (A. W. Bergen et al., 1999) Furthermore, assuming 
that multiple genes with small effects contribute to injection years, I performed a 
polygenic risk score analysis and pathway analysis in an attempt to ascertain which 
biological pathways are related to this variable. Figure 2 illustrates our hypothesis and 







Figure 1: Factors contributing to vulnerability to develop a specific addiction 




Table 1: Characteristics of genes related to heroin/opiate dependence and addiction 
Gene Protein System/Function Chromosomal location Associated SNP 
OPRM1 µ opioid receptor Opioid 6q24-25 rs1799971 
OPRK1 κ opioid receptor Opioid 8q11.2 rs963549 
rs1051660 
DRD4 Dopamine receptor D4 Dopaminergic 11q15.5 rs1800955, 
rs747302, 
rs936462 
TPH2 Tryptophan hydroxylase 2 Serotonergic 12q.21.1 rs4290270 
rs7963720 
HTR1B Serotonin receptor 1B Serotonergic 6q13 rs130058 
rs11568817 
SLC6A4 Serotonin transporter Serotonergic 17q11.1-q12  
COMT Catechol-O-methyl transferase Catecholaminergic 22q11.2 rs4680 





Figure 2: Heredity directly contributes to biological differences among individuals.+  
 
+ Sufficient research exists which suggests that there is a relationship between opioid dependence and opioid receptors; 
GWAS can connect heredity to the external phenotypes of IDU trajectory, injection years and HIV risk behavior. Our 
hypothesis is to determine if there is link between biology and external phenotypes. The solid line represents findings 
supported by the most up-to-date research. The dotted line represents our speculation. 
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Chapter 3: Injection years used to represent the 
longitudinal trends of injection drug use 
 
3.1 Abstract 
BACKGROUND: Substance use disorders are chronic and recurrent. Functional 
impairment and unstable lifestyles make it extremely difficult to collect comprehensive 
longitudinal data on IV drug users. Heroin users typically use needles putting them at 
high risk of HIV infection. Therefore, the study of a measured injected drug use trend 
from longitudinal data could provide useful information that will ultimately inform HIV 
prevention.  
METHODS: With data from the AIDS Linked to the Intravenous Experience (ALIVE) 
Study, this study uses a subgroup with GWAS data (N=1197). For each individual in the 
subgroup there are twenty-five years of longitudinal data and a single-nucleotide 
polymorphism (SNP). We devised a variable termed “injection-years”: the length of time 
an individual has been injecting drugs. A hot-deck multiple imputation procedure was 
used to address the problem of missing data. Models simultaneously imputing all data 
(Universal), using two prior visits as predictors (two predictor), and one prior visit (one 
predictor) as a predictor were used for imputation, and sensitivity tests were done for 
each model.  
RESULTS: The ALIVE GWAS subset includes 1,197 subjects, 98% African-American, 
287 (24%) females and 882 (76%) males with an average of 19 visits per person. There 
are 103,599 potential biannual total visits for all participants in the ALIVE GWAS subset, 
counting from the subject’s initial injection drug use to their most recent visit, but two-
32 
 
thirds of the data is missing. We imputed injection data across the ALIVE GWAS subset 
and the mean injection year phenotype is 23 years from the universal model, 19 years in 
the two-predictor, and 18 years in the one-predictor. Results of the sensitivity exam led us 
to choose the universal model for the analysis. The mean injection years is 24 (it is 23 
above), a result consistent with previous work in the ALIVE cohort (Genberg et al). 
LIMITATIONS: There is a large amount of missing data in the ALIVE GWAS subset 
but we recovered much of this data using imputation. Use of data beyond the single item 
indicating injection use, for example of injection intensity, may provide different results. 
CONCLUSION: We imputed with three models. Sensitivity test results supported the 
universal model, suggesting several causal factors influence injection behavior, including 
sex and age. After imputing using the universal model, we examined the mean of the sum 
of injection years across the sample and found it consistent with previous work which 
inferred injection careers using latent growth models.  
KEY WORDS: substance use disorder, addiction, injection, the ALVIE cohort, 
longitudinal data, imputation 
3.2 Introduction 
 Substance use disorders are chronic and recurrent. People with substance abuse 
disorders experience changes in behavior that impact their ability to function, and these 
changes may continue even after someone has quit using. Even worse, long-term 
addiction impairs intellectual function. Alcoholics, for example, are at high risk of 
Wernicke-Korsakoff Syndrome. (Thomson, 2000; Victor, Adams, & Collins, 1971) 
Intellectual functional impairment--specifically, cognitive impairment and poor 
judgement--can be found in addicts who regularly use opioid and amphetamines. (Ersche 
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et al., 2006) This functional impairment often translates into their not being able to hold 
down a steady job or to maintain healthy relationships; it is virtually impossible to follow 
up on them for lengthy periods of time. Collecting comprehensive longitudinal 
information from substance-dependent subjects is a challenging proposition; therefore, it 
is helpful to impute existing longitudinal data.  
There are several routes of drug administration: oral, sniffing or intranasal, and 
injection. Injection produces the fastest effects, often within minutes. Heroin is the most 
commonly injected drug; heroin addicts inject one to three times a day. Needles are often 
shared to save money. For these reasons, the administration of injection drugs is popular 
among regular drug users. In almost all cases, a person who is injecting drugs has a 
substance use disorder. 
HIV enters the bloodstream through transfusions of contaminated blood or blood 
products, through needle sharing among injection drug users, and through injections with 
unsterilized needles. (Friedland & Klein, 1987) Injection drug users are therefore at high 
risk of HIV infection and investigations such as the one performed here can be of benefit 
to this specific population, particularly because there have been few studies of this at-risk 
group. 
 In studying injection drug users, we need a quantifiable way to measure the 
intensity of their habit. This quantifiable measure must meet two requirements. First, it 
can be used to track changes in the frequency of injected drug use in our longitudinal 
dataset. Second, it may be associated with brain biology; in other words, it may link to 
specific genetic markers. In a study of smokers, the concept of “smoking pack-year” 
helped researchers to link pack-year history to a specific genetic region on chromosome 
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5q. (A. W. Bergen et al., 1999; Caporaso et al., 2009; Duggirala et al., 1999) Borrowing 
this concept, we create a phenotype, injection years. However, it is necessary to deal with 
a large amount of missing data before starting the analysis.  
Genberg et al., using latent growth curve modeling and longitudinal ALIVE 
injection data, found that I.V. drug users can be categorized into five different groups 
with unique trajectories: persistent injection, frequent relapse, early cessation, delayed 
cessation, and late cessation. (Genberg et al., 2011) In this study, using the same data we 
impute longitudinal injection data in the interest of creating a single injection years 
phenotype which we then compare to the inferred injection trajectories previously 
derived for this data set. 
3.3 Materials and Methods 
3.3.1 The ALIVE cohort  
With data from the AIDS Linked to the Intravenous Experience (ALIVE) Study, 
(Vlahov et al., 1991) this study uses  a subgroup with GWAS data (N=1197). Information 
about each individual in the subgroup includes up to twenty-five years of longitudinal 
data and genome-wide single-nucleotide polymorphism (SNP) data. The ALIVE study is 
a longitudinal prospective community-based study of I.V. drug users established in 1988. 
In its first decade, the ALIVE study attempted to understand the natural history of HIV 
within this population. Since 1998, ALIVE  has focused on participants’ access to, 
treatment for HIV and other non-AIDS outcomes including hepatitis C and the impact of 
those treatments (Galai et al., 2003; Vlahov et al., 1991)  
The initial enrollment in the ALIVE study was 2,938 participants eighteen years 
and older who had used injection drugs within the previous ten years. Seven hundred 
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were HIV seropositive. The first participants were 88% African-American, 81% male, 
with 77% reporting active injection. 1,733 recruits were added to the study in 1994-1995, 
1998, 2000, and 2005-2008. 
The ALIVE participants are divided into two cohorts. The ALIVE-I study follows 
a cohort of HIV-positive individuals and a sample of HIV-negative individuals; the 
ALIVE-II study follows a cohort of HIV- negative individuals. (Galai et al., 2003; 
Vlahov et al., 1991)  
3.3.2 Injection years and multiple imputation 
 In the COGA study, Bergen et al. created a novel variable, smoking pack-year, 
which was defined as the number of packs smoked per day for one year. This linkage 
study found that this external phenotype is associated with a gene region on chromosome 
5q. (A. W. Bergen et al., 1999) Caporaso et al. conducted a genome wide association 
study and linked a similar variable, cigarettes smoked per day, to several genetic markers. 
(Caporaso et al., 2009) Borrowing their concept, we sought to create a variable, injection 
years, which we define as the number of years a person has been using injected drugs. 
We posit that there is a strong possibility that this variable is a better reflection of the 
biological mechanisms underlying substance dependence and more likely to be associated 
with specific genetic markers. However, before we could proceed we had to develop a 
strategy to deal with the large amount of missing data in the ALIVE GWAS subset. 
Wang et al. demonstrated a hot-deck multiple imputation procedure in longitudinal data. 




The ALIVE GWAS subgroup is our study sample (N=1197). The dataset 
comprises a panel of binary variables representing positive (‘1’) or negative (‘0’) reports 
of injection use twice annually. Each row contains a single subjects injection history 
coded from age 20 to age 60, with preprocessing to include known but not directly 
assessed measures. For example, all data points prior to the age of first use were coded to 
‘0’ and the data point at the age of first use was coded to ‘1’. For the remaining data, we 
used all existing reports from each participant between the ages of twenty and sixty and 
treated all other non-available reports as missing data. Variables were aligned by age, 
thus each column represents injection in the sample at a specific 6 month age time-point. 
I also included two covariates as predictors in each model: gender and age of first 
injection. I compared three imputation models since longitudinal imputation models that 
account for temporality and are useful for binary data are not widely available. The three 
approaches are termed: universal, two-predictor and one-predictor. In the universal model, 
we used all existing reports as predictors. In the two-predictor model, we used two types 
of existing reports, six months prior and six months later. In the one-predictor model, we 
used only the six months prior report. We used multivariate imputation by chained 
equations to fill in missing data. (Buuren & Groothuis-Oudshoorn, 2011; C. N. Wang et 
al., 2011) Multiple imputation by chained equations was performed by using the program 
ice in Stata 12. (Royston, 2011; StataCorp, 2011) Multiple imputation by chained 
equations (or MICE) refers to an approach where, given a set of data with missing values 
across multiple variables, one variable is imputed at a time as the predicted value from a 
regression (logistic in this case) of the other variables. After imputation of the first 
variable, the second variable is imputed using the observed and imputed values of all 
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other variables, and so on. To estimate uncertainty or variance in the imputation estimate 
the approach can be repeated multiple times. For imputation in the ALIVE sample, 
number of iterations was five. We pooled all the imputations and calculated the average 
value from these imputed results. We then took the sum of the injection years for each 
participant to create the injection years variable. Sensitivity tests were done by random 
deletion of observed (ie, present in the actual data) raw data-points and re-imputing it to 
test accuracy. The number of re-imputations was ten for each model. We checked the 
rates of agreement between the observed data and the re-imputed data for these three 
models.  
3.3.3 Relationships between injection years and HIV 
trajectories 
Genberg et al. conducted an analysis of latent classes of drug use trajectory using 
a subsample of 1,716 individuals who had made at least eight follow up visits. (Genberg 
et al., 2011) Semi-parametric latent class growth mixture modelling was used to 
determine the number of latent drug use trajectories. (Nagin, 2005) In their final model, 
five distinct patterns were identified: persistent injection, frequent relapse, early 
cessation, delayed cessation, and late cessation. Three trajectories were associated with 
cessation. The early cessation group showed a sharp decline during the first five years, 
while the delayed cessation and late cessation groups displayed less steeply declining 
injection levels after approximately ten and fifteen years, respectively. Figure 3 shows 
the results of the latest publication from the ALIVE study exploring the trajectories of 
injection drug use.  
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Using the same ALIVE cohort, we created the measure, “injection years”, to 
assess the intensity of injection drug use. Like Genberg et al.’s studies, this study focuses 
on injection drug use and analyzes the ALIVE longitudinal dataset. The goal is to 
determine whether there is a correlation between injection years and the trajectories of 
injection drug use.  
3.3.3.1 Latent class growth model 
Latent growth modeling approaches, including latent class growth analysis and 
growth mixture modeling, are most commonly used in the social sciences when tracking 
longitudinal trajectories of individuals. (Jung & Wickrama, 2008) MacCallum et al 
reviewed the applications of latent growth curve models in psychological research that 
used a data set with longitudinal and repeated measure variables, concluding that it is a 
powerful tool with great benefit in psychological research. (MacCallum & Austin, 2000) 
These models have been used to understand inter-individual differences in intra-
individual change over time. (Nesselroade, 1991) The source dataset, the ALIVE study, is 
a prospective longitudinal study with repeated measures. There are precedents for 
applying latent growth models in this study. 
Latent growth modeling approaches have previously been applied to longitudinal 
drug use data in other cohorts. Hill et al suggested that patterns of alcohol use can be 
classified into four trajectory groups: “early highs”, “increasers”, “late onsetters”, and 
“non-bingers”. (Hill, White, Chung, Hawkins, & Catalano, 2000) Jackson et al. found 
four trajectory classes, using growth mixture modeling with five indices of alcohol 
consumption. (Jackson & Sher, 2005) The Hill and Jackson studies suggested that a 
heterogeneity of growth trajectories exists within the larger population and furthermore, 
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that the conventional growth models, which assume that an entire population only has a 
single growth trajectory are oversimplified. Because this study focuses on a similar type 
of dependency (the injection behavior of addicts) these same theoretical frameworks can 
be used to divide the entire population into several subgroups. 
Unlike the conventional growth model, growth mixture models make it possible 
to estimate the subpopulations within the entire population and to provide separate 
growth models for each latent class with its own estimates of variances and covariate 
influences. (Muthén & Asparouhov, 2008) Latent class growth analysis is a type of 
growth mixture model. The assumption of latent class growth analysis is that the variance 
and covariance estimates within each class are fixed to zero, assuming all individual 
growth trajectories within a class are homogenous. This approach serves as a preparation 
for identifying the distinct classes before developing general mixture models. (Kreuter & 
Muthén, 2007)  
 3.4 Results 
The ALIVE GWAS subset includes 1,197 participants drawn from the ALIVE 
cohort in 1998. The median age at first visit was 34. There were 287 (24%) females and 
882 (76%) males. They visited semiannually with 19 average visits per person. This 
translates into about 9 years of information on each subject. The population was 
predominantly African American (98%). About half of the participants were HIV positive 
when they entered the ALIVE cohort. 1,029 participants were injection drug users when 
they entered the study, while only 502 were still using injection drugs as of their last visit. 
When they first entered the study, the number of participants who were using more than 
once a day, less than once a day and not using were 449, 415, and 159, respectively. After 
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13 years in the program, 231 of the 496 injection drug users were still using more than 
once a day. Table 2 shows the characteristics of the GWAS subset in the ALIVE cohort. 
 In the ALIVE GWAS subset, the mean age of first injection was 21, and the 
histogram is right-skewed. More than half used for the first time between ages 14 and 26. 
The mean age of participants entering the cohort was 34. The years between first use and 
entering the program were regarded as missing data, although one discreet point was 
extracted: age at first injection. Figure 4 shows the distribution of ages at first injection 
and baseline age upon entry. 
To obtain our target variable, injection years, we needed to have information 
regarding injection status after age of first injection. This presented a problem since so 
much data was not available. There were 103,599 visits recorded for all the participants 
in the ALIVE GWAS subset, but this represented just one-third of all potential data from 
the age of first use forward: 66 percent was missing. The largest gaps of information 
occurred in injection status between the ages of 20 and 30:  75 percent of the data was not 
recordable. In other words, the younger the participant, the greater the likelihood of 
unretrievable information. Table 3 shows the distribution of missing data in the ALIVE 
GWAS subset. 
 We imputed the ALIVE GWAS subset with three models: universal, two-
predictor, and one-predictor. Respectively, the mean of the summary of injection years 
was 23, 19, and 18 years in the universal, two-predictor, and one-predictor model. The 
mean of the summary of injection years in the universal model was much greater than 
that of the other two models. In the universal model, we used all other existing data to 
impute the missing data. Considering there were more “Use” reports between the ages of 
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30 and 40 and 40 and 50, we imputed more “Use” reports than with the other two models 
in the age range 20 to 30. Figure 5 shows the distribution of the imputed injection years 
of 1,279 individuals from the ALIVE GWAS subset. 
Five percent of the fields from the injection data were randomly selected and were 
treated as missing data. We imputed these data ten times with each of the three models. 
We compared the imputed injection data with the original injection data and calculated 
agreement percentage and Kappa for each model. The findings suggested that the highest 
value for kappa occurred in the universal imputation model. Table 4 shows the actual 
value and imputed result agreement in these three models.  
After conducting the sensitivity exam for these three imputation models, we chose 
the universal model for the subsequent analysis. The individuals who were enrolled in 
both the ALIVE GWAS group and Genberg’s study were divided into five groups. 
(Genberg et al., 2011) The mean injection years were 17, 22, 22, 24, and 29 for early, late, 
delay, relapse, and persistent groups, respectively. As predicted, the persistent group had 
the highest mean injection years, and the early quit group had the lowest. For the 
overlapping group, the mean injection years was 24, a result consistent with that of 
Genberg et al. (Genberg et al., 2011) Table 4 shows the distribution summary of 
injection years among the different trajectory groups of injection drug users. 
3.5 Discussion 
Substance use disorders have a huge impact on public health and personal health. 
Illicit psychoactive drugs are associated with a variety of psychological and physical 
problems. From a public health perspective, in the U.S. there is an enormous societal cost 
to the use of drugs like opioids. (Birnbaum et al., 2011)  The costs to the health care and 
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criminal justice systems, combined with losses in workplace productivity, add up to $50 
billion annually. (Birnbaum et al., 2011; Hansen et al., 2011) From a personal health 
perspective, injection drug use leads to a whole host of physical problems and one of the 
most serious is the high risk of acquiring HIV. (Friedland & Klein, 1987) There have 
been few studies of this specific population; we therefore hope this study can be of 
benefit to this group and to those working on all fronts to help them. 
Substance use disorders are chronic and recurrent. Changes in behavior patterns 
are common among individuals with substance abuse disorders and may continue even 
after a person has quit using. For example, alcoholics may be irritable and impulsive even 
after many years of sobriety. Observing the changes in long-term behavior patterns can 
perhaps help us to understand more about the outcomes of addiction. As stated previously, 
it is almost impossible to track and collect data from a highly unstable population such as 
substance dependent individuals for any length of time, much less the amounts of time 
required for this study. The longer the study, the higher the amounts of missing data. In 
the ALIVE GWAS subset, investigators tracked their subjects for approximately ten 
years; thus, there are vast amounts of missing data. In studying injection drug users, we 
borrowed the concept of “smoking pack-year”, which helped researchers to link pack-
year history to a specific gene region on chromosome 5q. (A. W. Bergen et al., 1999; 
Caporaso et al., 2009; Duggirala et al., 1999) We created a phenotype, injection years, to 
track changes in the status of injected drug use in our longitudinal dataset. We found that 
it is necessary to account for the large proportion of missing data before starting the 
analysis. For this purpose, we imputed missing longitudinal data in this study. 
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In this study, we imputed the ALIVE GWAS subset with three models: universal, 
two-predictor, and one-predictor models. In the ALIVE GWAS subset, there is more data 
missing inform the earlier phases of injection use than in the middle and late phases. In 
the universal model, we used all the existing reports as predictors with age of first 
injection and sex, so the imputed reports in the early phase were influenced by the 
existing reports in the middle and late phases; we supposed that several causal factors 
continuously influence injection behavior in all phases. In the two-predictor model, we 
used the two kinds of existing reports, six months prior and six months later, as predictors 
with age of first injection and sex, so the imputed reports in all phases were only 
influenced by those existing reports which were closest in time. We supposed that causal 
factors which influence injection behavior change in different phases but may remain the 
same in the identical phase. In the one-predictor model, we used only the existing report, 
six months prior plus age of first injection and sex, as a predictor, so the imputed reports 
were only influenced by the existing reports at the identical time point. The results of the 
sensitivity test support the universal model. Using the universal model, the mean of the 
sum of imputed injection years is consistent with the results of previous work in the 
ALIVE Cohort. (Genberg et al., 2011)  
 This study had a number of limitations. The first was the amount of missing data 
in the ALIVE GWAS subset. Overall, sixty-six percent of the possible data regarding the 
injection career is missing, if we include the time period between a subjects first injection 
and entry into the Cohort and assume that a visit was possible twice annually. The 20 to 
30 year age range actually has a 75 percent rate of missing data under these parameters. 
The accuracy of imputation is associated with the amount of existing data. These amounts 
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of missing data would definitely decrease the accuracy of imputation. Second, the 
definition of injection years is the number of the years the person has been injecting 
drugs; we only focused on the length of injection time and ignored the dosage and the 
injection counts. Although we think our study target, the natural trend of injection 
behavior, is mostly influenced by the injection years, we cannot exclude the possibility 
that our study target is also influenced by these other factors.  
 Using the universal imputation model, we got the mean of the sum of injection 
years which was similar to previous work in the ALIVE Cohort. (Genberg et al., 2011) 
The findings of this study support the use of multiple imputation in a longitudinal cohort 
such as the ALIVE GWAS subset. Clearly, missing data presents a major obstacle for 
conducting longitudinal studies; multiple imputation using specific models may provide a 
solution to this problem. We highly recommend using multiple imputation in other 
longitudinal studies and to examine the accuracy and reliability of the imputed data.  By 
using the appropriate model, we believed that reliable imputed records could be obtained 
from the existing records. Another potential area for future studies is to use multiple 
imputation to impute continuous variables such as the injection counts. Caporaso et al. 
used the concept of “smoking pack-year,” which is defined as the number of packs 
smoked in a year.  (Caporaso et al., 2009)  In this study, we did not deal with the intensity 






Figure 3: Trajectories of Injection Drug Use Among 1,716 Injection Drug Users in The AIDS Linked to The Intravenous 
Experience (ALIVE) Study, Baltimore, Maryland, 1988–2008.+  
 
+ “The dotted lines represent the predicted probabilities of injection drug use conditional on membership in one of the 5 drug-use groups, while the solid lines represent the observed proportion of 
injection drug use given group membership. The y-axis represents the conditional probability of injection drug use, while the x-axis reflects time since study enrollment. The 5 groups (and prevalence of 




Table 2: ALIVE GWAS sample N=1197 
 First follow up visit Last follow up visit 
Age(median & IQR) 34(30-39) 47(40-53) 
Female 287(24%) 287(24%) 
African American 1169(98%) 1169(98%) 
HIV positive 627(52%) 828(69%) 
Current user 1029(86%) 502(42%) 
































































Table 3: Distribution of missing data in the ALIVE GWAS subset 
Injection status of last 6 months Not use (%) Use (%) Missing (%) Total 
Age 20 to 60 19,398 (18.72) 15,001 (14.48) 69,200 (66.8) 103,599 
Age 20 to 30 4,715 (18.93) 1,506 (6.05) 18,685 (75.02) 24,906 
Age 30 to 40 4,129 (15.53) 6,699 (25.50) 15,758 (59.27)  26,586 







Figure 5: Distribution of the imputed injection years of 1,279 individuals from the 




Table 4: Actual value and imputed result agreement in one predictor, two predictor 
and universal imputation models 
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Table 5: Distribution of the summary of injection years among different trajectory 
groups of injection drug user+ 
Sum of Injection years      Participants Mean(S.D.) Min Max 
Injection trajectory groups          
Early 153 16.9 (5.36) 1.3 28.3  
Late 146 21.5 (5.30) 7.3 32.3  
Delayed 149 22 (4.12) 11.5 30.9  
Relapse 152 24.25 (4.92) 12.4 37.5 
persistent 299 29 (4.95) 13.9 39.9  
Total 899 23.87 (6.63) 1.3 39.9 
+ The detail of the trajectories of injection drug use among 1,716 injection drug users in the ALIVE Study were 










Chapter 4: Measuring genetic influence on 




BACKGROUND: Opioid addiction is heritable. We posit that injecting heroin may have 
genetic underpinnings. Using the ALIVE cohort, Genberg et al. tracked the trajectories of 
intravenous drug users and categorized them into five groups. It was possible to quantify 
injection behavior patterns. We devised the injection years variable to quantify the 
duration of longitudinal injection behavior. We propose that this variable may have a 
genetic basis. 
METHODS: The AIDS Linked to the Intravenous Experience (ALIVE) GWAS cohort 
(N=1197) was used. Each subject has twenty-five years of longitudinal data and a single-
nucleotide polymorphism (SNP). We created a variable, injection years, the length of 
injection time. Genome wide association analysis was used to examine the associations 
between genetic factors and injection years. Data management, genotype quality control, 
population stratification, and correction for multiple testing were conducted.  After a 
genome wide association analysis, a polygenic risk score analysis and a pathway analysis 
were performed.   
RESULTS: Using PLINK, 1,107 people and 735,081 variants passed filters and quality 
control. Phenotype data, injection years, is quantitative. Using regression analysis, we 
tested the SNP associations after adjusting for gender and genome-wide ancestry 
covariates. No single SNP in the GWAS reached the level of genome-wide significance. 
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Eleven SNPs exceeded the p < 5 × 10−5 threshold, including one SNP (rs10168062) with  
p < 5 × 10−7. The closest SNP with a previous report of a genome-wide significant 
association result is rs7602960 which is associated with memory. The findings from a 
polygenic risk score analysis support a polygenic basis for injection years that involves 
many common SNPs. 31 intervals and 5,225 gene sets from Gene Ontology (GO) terms 
were used in a pathway analysis. None of the gene sets was statistically significant. The 
top two gene sets were metallocarboxypeptidase activity and DNA dealkylation which 
are involved in DNA repair.  
LIMITATIONS: Genetic and environmental factors are inextricably linked. There is 
insufficient data for a powerful polygenic risk score analysis. 
CONCLUSION: We used longitudinal addiction behavior to perform genome-wide 
association analyses. The result suggested that injection years might be affected by 
polygenes. Polygenic risk score analysis further supported this conclusion. The findings 
from pathway analysis suggest that DNA repair may play a role in our risk phenotype, 
injection years. Using injection years as a phenotype in genome wide analysis proved to 
be a successful way to explore genetic influences on specific behavior traits in a 
longitudinal cohort.  
KEY WORDS: injection years, GWAS, polygenic risk score, pathway analysis 
4.2 Introduction 
As we reviewed in chapter 2, substance use disorders are heritable; many articles 
provide evidence to support the role of genetics in nicotine dependence and alcohol use 
disorders. Heroin, one of the notorious illicit drugs, had the greatest overall genetic 
variance, 0.54. (Tsuang et al., 1998) Kreek et al. demonstrated that developing substance 
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use disorders may be partly due to heritable factors through underlying behavioral risk 
dimensions like impulsivity and risk taking. (Kreek et al., 2005) Her conclusion 
suggested that specific behavior patterns related to addiction are associated with genetics. 
Borrowing her concept, we believe that injection, a harmful behavior related to heroin 
addiction, may be associated with genetics. Injection drug use affects personal health and 
wellbeing through transmission of blood-borne diseases; moreover, it causes huge losses 
in a nation’s economic productivity.  
The ALIVE study is a longitudinal prospective community-based study of 
injection drug users in Baltimore. It provides valuable information of injection behavior 
patterns and HIV risk behaviors from a group of injection drug users for twenty-five 
years. By tracking the trajectories of injection drug users, we can categorize the ALIVE 
cohort into several subgroups: early quit, persistent, and relapse group or quantify the 
ALIVE participants’ injection behavior patterns. Bergen et al. developed a novel variable, 
smoking pack-year, and their linkage study found that it is associated with a gene region 
on chromosome 5q. (A. W. Bergen et al., 1999) Using genome wide association analysis, 
Caporaso et al. associated a similar variable, cigarettes smoked per day, to several genetic 
markers. (Caporaso et al., 2009) We borrowed this concept to formulate a variable, 
injection years, to quantify the intensity of longitudinal injection behavior. In this chapter, 
we examined whether this variable is associated with SNPs, both singly and in composite 
as polygenic or systems-level scores. Furthermore, in order to reveal the associated brain 
mechanism, we used the existing dataset to examine whether our findings links to the 
specific proteins or receptors.  




 The AIDS Linked to the Intravenous Experience (ALIVE) Study was used in our 
study. (Vlahov et al., 1991) More specifically, we used the subgroup with genome-wide 
single nuclear polymorphism data (N=1197) from the ALIVE cohort. The details of the 
ALIVE cohort have been already described in the chapter 3.  
4.3.2 Selection of phenotypes for longitudinal injection 
information 
 In 1999, Bergen et al. conducted a linkage study and found smoking pack-year is 
associated with a gene region on chromosome 5q. (A. W. Bergen et al., 1999) In 2009, 
Caporaso et al. conducted a genome wide association study and linked a similar 
phenotype, cigarette smoked per day, to several genetic markers. (Caporaso et al., 2009) 
As well as smoking, we believe that genetics have a high probability to be involved in 
injection behaviors. The procedure of developing our phenotype, injection years, and the 
detailed description of the relationship between genetic influences and drug use behavior 
and more specifically, the previous successes in drug use genetics by studying variable 
use behavior in drug using populations has been already described in the chapter 3.   
4.3.3 Genome wide association analysis 
A genome wide association study is a way of measuring and analyzing common 
DNA sequence variations, in particular single nucleotide polymorphisms, to determine 
whether a variant is associated with a specific trait from a common disease in the 
population.(Hirschhorn & Daly, 2005) Single nucleotide polymorphisms are single base-
pair changes in the DNA sequence, occurring in more than one percent within a 
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population; such variants are also regarded as potential genetic risk factors or as proxies 
for nearby SNPs in linkage disequilibrium.(Genomes Project Consortium, 2010) A goal 
of human genetics is to identify genetic risk factors for traits or diseases. This goal was 
partly achieved by identifying the genetic risk factors for rare Mendelian diseases such as 
cystic fibrosis using linkage analysis. (Kerem et al., 1989) This approach has been also 
successfully applied to other rare diseases such as Huntington’s (MacDonald et al., 
1992) , but it failed to identify the genetic risk factors for common diseases like various 
types of cancer and schizophrenia. This led to the common disease/common variant 
hypothesis which states that common diseases are likely influenced by genes that are also 
common in the population. (D. E. Reich & Lander, 2001) Assuming the validity of the 
common disease/common variants hypothesis, the first successful genome wide 
association study was published in 2005, identifying the Complement Factor H gene for 
age related macular degeneration. (Haines et al., 2005) Unlike genome association studies 
or candidate gene studies, genome wide association studies search the entire human 
genome instead of focusing on a small number of candidate gene regions. This approach 
has now been applied to numerous common diseases; the National Human Genome 
Institute GWAS catalog lists over 3,600 SNPs implicated in common diseases or traits. 
(Hindorff et al., 2009)  
The most common study design among genome wide association studies is the 
case-control study in which the case group is affected individuals and the control group is 
healthy individuals. An alternative to the case-control study is the quantitative phenotype, 
as opposed to the binary phenotype, for example using a variable such as height. All 
individuals are genotyped for common SNPs, most frequently using one of two primary 
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platforms: Illumina (San Diego, CA) and Affymetrix (Santa Clara, CA).  The data form 
of GWAS analysis includes two basic parts: phenotype and genotype. The phenotype 
data contains demographic information such as gender, age, and risk phenotypes. This 
information will be obtained from the former chapter. The genotype data was obtained 
from genotyping. Because GWAS data contain vast amounts of information on genotype 
(750,000 SNPs for individual) I needed to consider a number of issues to deal with large 
scale that need to be addressed before, during or after genome wide association testing. 
These issues include data management, genotype quality control, population stratification, 
genotype imputation, and correction for multiple testing. Quality control procedures 
discard genotypic information of poor quality—for example, poor calling rates. 
Population stratification adjusts for the different geographical and ethnical backgrounds 
of participants. Genotype imputation increases the number of SNPs that can be tested for 
association and increases the power of the study. Correction of multiple testing prevents 
type I errors.  
In this study, I analyzed larger scale genetic association data with the appropriate 
computing hardware: the High Performance Computing Center at the JHSPH, and 
software which will include PLINK and R. In addition to the appropriate devices and 
software, the advisor to this study, Dr. Brion Maher, has considerable experience 
managing large datasets and has also been a primary analyst on several GWAS projects. 
The conductor of this proposed study, Shaocheng Wang, has already taken the required 




Genome wide association analysis may bring an increase in the number of false 
positive associations because of biases in study design and errors in genotype calling. 
Several quality control steps will be taken to remove individuals or makers with 
extremely high error rates in order to avoid these false positive associations. First, I 
identified and eliminated subjects with discordant sex information. Second, because the 
impact of removing a potential marker is greater than the removal of one individual, I 
implemented quality control on a “per individual” basis prior to conducting quality 
control on a “per-marker” basis. (Anderson et al., 2010) I eliminated subjects with high 
levels (>5%) of missing genotypes and then eliminated markers which exhibited high 
levels (>5%) of missing data. Third, I tested Hardy-Weinberg equilibrium (HWE) in 
order to eliminate markers that exhibit large deviations from expected genotype 
distribution. I eliminated markers exhibiting Hardy-Weinberg disequilibrium (p < 
0.00001). By using these stringent criteria, I attempted to avoid the inclusion of markers 
exhibiting systematic genotyping errors. In brief, the purpose of the above quality control 
measures is to ensure data precision and ultimately to detect true genotype phenotype 
relationships. 
In GWAS, population substructure may cause bias from systematic differences 
between cases and controls or between individuals at extremes of the phenotypic 
distribution. Differences in phenotype prevalence by ethnicity and in allele frequencies 
by ethnic sub-population highlight the notion that specific genetic markers may be more 
likely associated with the diseases/traits spuriously because of population stratification. I 
applied multidimensional scaling as implemented in PLINK to generate genome-wide 
ancestry covariates prior to performing GWAS to examine the relationships between 
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genotype and phenotype. I used complete linkage agglomerative clustering based on 
pairwise identity-by-state distance.  
In a genome wide association study, hundreds of thousands of tests are conducted, 
which means the cumulative likelihood of finding one or more false positives is higher 
than if only one test is done. Several simple techniques are used to correct for multiple 
testing. These include Bonferroni correction, permutation testing and adjusting for false 
discovery rate (FDR). In this study, I focused on Bonferroni correction. (Gao, Starmer, & 
Martin, 2008)  
4.3.4 Polygenic risk score and Pathway analysis 
After obtaining the results from genome wide association analysis, we planned to 
conduct a polygenic risk score analysis and a pathway analysis. The polygenic risk score 
analysis creates a score from the top SNPs from the GWAS on our target phenotype and 
the pathway analysis tests whether the top SNPs from the GWAS of our target phenotype 
yield information on the possible biological mechanisms due to an enrichment of SNPs in 
genes in specific biological pathways. Both approaches are commonly used to examine 
the common disease-common variant hypothesis.  
The polygenic risk score analysis is a statistical approach which is used to 
summarize genetic effects among a group of SNPs which do not have significant 
associations with diseases/traits. The approach is based on the assumption that although 
many SNPs do not reach significance after correcting for genome-wide testing, the tail of 
the distribution of p-values less than some target threshold will be enriched for true 
signal. A GWAS is conducted first on a training sample and the p values of SNPs are 
obtained. A polygenic risk score is then constructed in an independent sample, as a 
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weighted sum scores trait-associated alleles for each subject, for different subsets of top 
ranking markers.(Dudbridge, 2013)  
The first successful polygenic score analysis in/within a GWAS was applied to 
schizophrenia and bipolar disorder.(Purcell et al., 2009) This approach has two possible 
applications. First, the polygenic scores can be used to determine the association between 
a disease/trait and selected SNPs. Second, the polygenic scores can be used to predict 
individual disease/trait value. This approach has attracted much attention and has been 
used with several common and complex disease including multiple sclerosis, 
cardiovascular risk, and rheumatoid arthritis.(Consortium, 2010; Simonson, Wills, Keller, 
& McQueen, 2011; Stahl et al., 2012) In this study, I applied polygenic risk score analysis 
using the injection years phenotype to search for associations between selected genetic 
risk factors and addiction, and the findings of polygenic risk score analysis have the 
potential to be used as a prediction tool for injection years. The male group is used as 
discovery sample and the female group is our target sample. 
In order to compensate for the limitations of GWA studies, several alternative 
approaches to GWA studies have been developed in recent years. In this section, I focus 
on one of them, the pathway analysis. Unlike the analysis of a single marker as is the 
method in a GWAS, pathway-based approaches examine whether a group of biologically 
related genes which are discovered from previous research have significant association 
with a disease/trait.(K. Wang, Li, & Hakonarson, 2010) Most common and complex 
diseases are caused by the interaction of multiple genes which involve complex 
molecular networks and cellular pathways.(Schadt, 2009) In brief, a pathway-based 
analysis is an alternative to GWAS by combining association results with known 
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biological pathways; it also offers a biological interpretation of diseases/traits, in 
particular risk phenotypes used in GWAS.(Cantor, Lange, & Sinsheimer, 2010)   
Pathway based analyses have been used with several neuropsychiatric disorders. 
The associations between the pathway of neuronal cell adhesion molecules and either 
autism, schizophrenia or bipolar have been examined in two studies.(O'Dushlaine et al., 
2010; K. Wang et al., 2009) In addition, a pathway analysis found ion channel activity 
and synaptic neurotransmission to be associated with bipolar disorder.(Askland, Read, & 
Moore, 2009; Holmans et al., 2009)  
In this study, I used pathway analysis with one of the most common of 
neuropsychiatric disorders: addiction. I used the GWAS results from our previous work 
and performed a pathway analysis. I used the software tool, Interval-based Enrichment 
Analysis Tool for Genome Wide Association Studies (INRICH), to perform our pathway 
analysis and the reference biological pathways were obtained from the Gene Ontology 
(GO). (Lee, O'Dushlaine, Thomas, & Purcell, 2012)  
4.4 Results 
Using PLINK, we applied multidimensional scaling to generate genome-wide 
ancestry covariates prior to analyzing the genome wide associations. None of the 1,171 
subjects was excluded because of population stratification. The calculated ancestry 
covariates were used to account for genetic ancestry in subsequent association analysis. 
Before quality control, there were 1,171 individuals and 906,709 genotypes in the 
ALIVE GWAS cohort. Because of missing genotype data, 64 subjects had to be excluded. 
Additionally, 59,813 variants were removed also due to missing genotype data. 13,578 
variants were excluded from the analysis due to departure from HWE exceeding α = 
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0.00001. Another 98,237 variants were removed due to minor allele threshold. In the 
final analysis, 735,081 variants and 1,107 participants passed filters and quality control.  
 The injection years phenotype data is quantitative. Using regression analysis, we 
tested the SNP associations after adjusting for risk factors such as gender and eight 
genome-wide ancestry covariates. We found that no single SNP in the GWAS reached 
the level of genome-wide significance. (p < 5 × 10−8) (Figure 6) However, eleven SNPs 
exceeded the p < 5 × 10−5 threshold, including one SNP (rs10168062) with a p < 5 × 10−7. 
(Table 5) The closest SNP is rs7602960 which is associated with memory. (Seshadri et al., 
2007) 
 Because the ALIVE GWAS subset is unique, it is not possible to find another 
independent GWAS sample with which to replicate the polygenic risk score analysis. We 
followed the process described in the supplementary information in Purcell’s article 
(Purcell et al., 2009) and divided the ALIVE GWAS sample into a female group (N=287) 
and a male group (N=910). We used the ALIVE GWAS male group for the discovery 
sample, considering four PT thresholds (arbitrary p-value thresholds below which all 
SNPs are summed) from the intra-ALIVE GWAS male group analyses. The ALIVE 
GWAS female group was used as our target sample. The male-derived polygenic risk 
scores were highly positively correlated with injection years in the entire ALIVE GWAS 
subset. The value of correlation coefficient is 0.7420077. (Supplementary Figure. 1) 
Using the male-derived scores in the female group with different PT thresholds, the 
correlation coefficient increased and then reached a plateau as the PT increased. 
(Supplementary Figure. 1, Figure. 7) The highest correlation coefficient is 0.1041739 
when PT is 0.01. However, due to the relatively small sample size, the correlation was not 
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statistically significant. In conclusion, the ALIVE GWAS subset suggested that injection 
years involve many common SNPs. 
 Using Interval-based Enrichment Analysis Tool for Genome Wide Association 
Studies (INRICH), we performed Gene Ontology (GO) enrichment analyses. Human 
genome references, hg19, were obtained from the UCSC Genome Browser. I selected the 
SNPs which reached the PT < 0.0001 and the linkage disequilibrium is under 0.5 from our 
genome wide association analysis results with risk phenotype as injection years. 61 
clumps (interval) were formed from 78 top SNPs. I excluded 22 intervals which were not 
on gene regions and 8 intervals which were overlapping; 31 intervals remained in the 
pathway analysis. After merging and size filtering, we restricted the analysis to terms 
with at least 3 human genes and considered gene sets with at least 2 overlapping 
intervals, leaving 5,225 from the total 10,365 GO terms. A permutation procedure was 
conducted to rule out the probability of observing the number of intersecting intervals by 
chance alone. We repeated the first-pass permutations and second-pass permutations 
1,000 times each to correct for bias from multiple testing. The corrected P values account 
for the dependence of the GO terms. 
 These 31 intervals were selected for the pathway analysis, but none of the gene 
sets proved to be statistically significant. One of the top gene sets is 
metallocarboxypeptidase activity, including AGBL4 (ATP/GTP binding protein like 4), 
CPM (Carboxypeptidase M), CPE (Carboxypeptidase E), and AGBL1 (ATP/GTP binding 
protein like 1). Another is DNA dealkylation involved in DNA repair, including MGMT 
(O-6-methylguanine DNA methyltransferase), and ALKBH2 (AlkB, alkylation repair 
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homolog 2). (Table 6) In the global enrichment analysis, 6 and 77 unique genes have 
empirical p value less than 0.01 and 0.05, respectively. (Table 7) 
4.5 Discussion 
 In this study, we tested the association between longitudinal addiction behavior 
and genetic risk factors. Longitudinal studies of this population are rare; missing data is a 
common problem in such studies. Having access to the ALIVE GWAS cohort, a 
longitudinal community-based cohort, made this study possible. Using multiple 
imputation, we created a risk phenotype, “injection years”. This risk phenotype was used 
in the genome wide association analysis. However, no single SNP in the GWAS reached 
the threshold of genome-wide significance. Eleven SNPs exceeded the p < 5 × 10−5 
threshold; the top three findings were rs10168062, rs2200572, and rs10187215 clustered 
on chromosome 2, in an uncharacterized locus. The closest SNP with a previous 
association was rs7602960 that has been associated with memory. (Seshadri et al., 2007) 
This result suggests that injection years might be affected by polygenes and/or gene-gene 
interactions and/or gene-environment interactions, rather than by a single gene.  
Traditional genome wide association studies have to potential explain a large 
proportion of genetic risk factors for diseases but cannot detect genetic subsets in which 
each gene has a very small size effect without very large sample sizes. Polygenic risk 
score analyses and pathway analyses are used to detect those genetic subsets, using the 
results from a genome wide association analysis. Vink et al. examined polygenic risk 
scores for smoking and found that smoking, alcohol and cannabis use are influenced by 
many common genetic variants.(Vink et al., 2014) The results of Vink’s polygenic risk 
score analysis support the proposition that injection years are influenced by polygenes. 
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However, no significant results were found in the pathway analysis. The top two gene 
sets are metallocarboxypeptidase activity and DNA dealkylation involved in DNA repair. 
This suggests that DNA repair may play a role in our risk phenotype, injection year.  
There were a number of limitations in this study. First, we have proposed that 
gene-environment interactions may play a role, for example life events. However, in a 
longitudinal study like the ALIVE GWAS cohort, it is hard to identify and isolate an 
environmental variable that may have impacted drug use trajectories at a particular time 
point. Although our target is the trait of injection behavior, which is influenced by genetic 
factors, we cannot disentangle the interactions between genetic factors and environmental 
factors; the results of our analysis may be confounded by environmental factors. Second, 
there were only 1,200 research subjects.  Second, we only had 1,200 research subjects. 
Because there are so few studies of injection drug users, we were not able to find an 
independent sample to serve as a discovery sample for the polygenic risk score analysis. 
We attempted to make up for this by creating gender-based subsets. However, the 
numbers in these subgroups were not high enough for a satisfactory polygenic risk score 
analysis.  
Linking injection years to genetics, this study offers a practical method for 
exploring genetic influences on specific behavior traits in a longitudinal cohort. We 
believe that there are two areas that warrant future research. First, there have been few 
studies of the genetic influences on drug-related behavioral phenotypes; we believe that 
this study’s use of the latest techniques such as polygenic risk score analysis and pathway 
analysis provides valuable information on how genetic factors influence injection 
behavior. We have attempted to determine whether there is a large portion of genetic risk 
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for the phenotype of injection years, whether there are genetic subsets in which each gene 
has a very small size effect, and whether there are gene sets which influence specific 
biological pathways.  
Second, there are few studies of the genetic influences on longitudinal phenotypes. 
We used injection years to represent longitudinal trends in injection behavior. Though 
there are challenges posed by using a longitudinal cohort, we believe that genetic 
influences persist throughout a person’s life; thus, for the purpose of this research, the 
longitudinal study provides more valuable information than would a cross-sectional study. 
In conclusion, we recommend using behavioral phenotypes for genome wide analyses to 
test the association between genetics and observable behaviors; we believe that this 
method can provide valuable information about how genetic factors influence behavior 





Table 6: Top 20 SNPs, their chromosomal locations, minor alleles, test mode, numbers of non-missing individuals included in 
the analysis, β for linear regression, coefficient for t-test, and p-value. 











2 rs10168062 13418345 A/T ADD 1112 1.386 4.946 8.75E-07 
2 rs2200572 13450765 T/A ADD 1101 -1.412 -4.878 1.23E-06 
2 rs10187215 13459528 C/G ADD 1112 -1.38 -4.844 1.45E-06 
22 rs742837 43880111 A/T ADD 1111 -2.138 -4.79 1.90E-06 
2 rs13416262 13458652 G/C ADD 1113 1.293 4.594 4.84E-06 
12 rs12371640 124636328 A/T ADD 1112 -2.126 -4.587 5.02E-06 
6 --- 31134599 A/T ADD 1053 -1.92 -4.587 5.04E-06 
3 rs771795 101718657 T/A ADD 1096 -1.274 -4.54 6.25E-06 
9 rs12002290 136747854 C/G ADD 1093 1.577 4.539 6.29E-06 
11 rs666839 73346041 A/T ADD 1106 -1.434 -4.486 8.04E-06 
12 rs11067936 110144932 T/A ADD 1112 1.424 4.481 8.19E-06 
10 rs3781452 126355129 C/G ADD 1074 1.356 4.431 1.04E-05 
5 rs13174024 97930167 T/A ADD 1109 -1.719 -4.404 1.17E-05 
6 --- 31130019 C/G ADD 1112 -1.746 -4.401 1.18E-05 
7 rs10486704 41055230 T/A ADD 1113 -1.303 -4.398 1.20E-05 
2 rs6432374 13463725 G/C ADD 1108 -1.283 -4.393 1.22E-05 
11 rs537338 17926525 A/T ADD 1113 1.495 4.387 1.26E-05 
11 rs7940754 93345679 T/A ADD 1106 -1.783 -4.382 1.29E-05 
15 rs12440934 58425804 G/C ADD 1105 1.797 4.348 1.50E-05 
9 rs7869992 462759 C/G ADD 1100 -1.385 -4.317 1.73E-05 
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Figure 6: The manhattan plot of the p-values from all 735,081 SNPs. The x-axis shows the chromosome numbers. The y-axis is 
the-log10 (p-value). The blue line is p-value of 10−5. 
69 
 
Supplementary Figure 1: Correlation between injection years and polygenic risk 










Supplementary Figure 2: Correlation between injection years and polygenic risk 






Figure 7: Correlations between injection years and polygenic risk score with P value 




Table 7: Interval-based enrichment analysis results of Gene ontology (GO) biological processes for injection years.  




Empirical P Corrected P 
GO:0001516 prostaglandin biosynthetic process 12 4 0.030969 0.99001 
GO:0002576 platelet degranulation 77 5 0.030969 0.99001 
GO:0004181 metallocarboxypeptidase activity 25 4 0.00999001 0.906094 
GO:0005085 guanyl-nucleotide exchange factor activity 119 6 0.047952 0.999001 
GO:0006307 DNA dealkylation involved in DNA repair 6 2 0.00999001 0.906094 
GO:0006476 protein deacetylation 10 3 0.027972 0.987013 
GO:0006541 glutamine metabolic process 14 4 0.048951 0.999001 
GO:0007405 neuroblast proliferation 14 4 0.025974 0.984016 
GO:0008266 poly(U) RNA binding 6 3 0.038961 0.995005 
GO:0009881 photoreceptor activity 7 2 0.034965 0.992008 
GO:0010460 positive regulation of heart rate 7 4 0.028971 0.988012 
GO:0016477 cell migration 66 5 0.037962 0.994006 
GO:0018298 protein-chromophore linkage 15 3 0.014985 0.942058 
GO:0035609 C-terminal protein deglutamylation 3 2 0.025974 0.984016 
GO:0035610 protein side chain deglutamylation 3 2 0.025974 0.984016 
GO:0040007 growth 31 4 0.045954 0.999001 
GO:0042326 negative regulation of phosphorylation 15 3 0.045954 0.999001 
GO:0046887 positive regulation of hormone secretion 13 4 0.015984 0.948052 
GO:0048709 oligodendrocyte differentiation 11 3 0.034965 0.992008 
a Number of genes in gene set; b Number of associated intervals overlapping with genes in gene set 
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Table 8: Global interval-based enrichment analysis results under p value, 0.001, 
0.01, and 0.05 
P value threshold a Number of genes in the enriched 
pathways b 
Significance c 
<0.001 0 1 
<0.01 6 0.758242 
<0.05 77 0.703297 
a P-value threshold to select significantly enriched pathways; b number of unique genes in the enriched pathways with 
empirical p-value ≤ P value threshold; c % of bootstrapping samples where number of unique genes in enriched 












Chapter 5: Conclusion 
5.1 Review of guiding principles  
The goals of this dissertation project were to  a) review studies that link addiction 
to injection behavior and to genetics, b) apply a selected multiple imputation model to 
manage the large amount of missing data in the longitudinal study, c) create a risk 
phenotype for genome wide analysis.  
Substance use disorders are chronic and recurrent. In order to study HIV risk 
behaviors like the injection of addictive drugs, data from a longitudinal study rather than 
a cross-sectional study yields more useful information. The reason is that a longitudinal 
database provides more valuable information about the long-term trajectories of the HIV 
risk behaviors of injection drug users. Using this longitudinal sample, we borrowed the 
concept of “smoking pack-years” to create a phenotype, injection years. (Caporaso et al., 
2009) However, the lives and relationships of injection drug users tend to be unstable; 
hence, there exists virtually no perfect attendance record for any single participant in this 
study. Using the ALIVE cohort, a longitudinal community-based study, I created three 
imputation models and examined them by sensitivity test. The results of the universal 
imputation model served as the basis for the genome wide analysis. 
The ALIVE cohort is a longitudinal community-based study of IV drug users. 
This urban minority population is at high risk of illicit drug use and dependence (Reuter 
et al., 1998) yet there is scant research on the association between their genetic makeup 
and HIV risk behaviors. I believe that the findings may enhance prevention and treatment 
strategies and aid in identifying subpopulations at high risk of persistent drug use. In 
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addition, in studying this target population we avoid a common pitfall of genome wide 
association analyses: the use of samples from different geographical regions with 
individuals of different genetic backgrounds. In other words, population stratification, 
which is a major quality control issue in GWAS, was not a big concern in this study. Still, 
GWAS have limitations. The first is that current diagnostic categories might not reflect 
the heritability of a particular disorder. (Psychiatric GWAS Consortium Coordinating 
Committee, 2009) Borrowing the concept of “smoking pack-years,” I created a sub-
phenotype, injection years. I believe that this phenotype may be at least partly genetic in 
origin; moreover, this phenotype can be used to measure the intensity of injection 
behavior. It is hoped that this finding will elucidate our understanding of modifiable and 
fixed components of injected drug use, a major HIV risk behavior, in this population, and 
lead to improved treatment and prevention. 
In this thesis, I have attempted to link behavioral phenotypes with genetics. The 
genetic underpinning of substance use disorders is an area of great interest. Classical 
genetic approaches have shown that addiction is heritable; molecular genetic approaches 
suggest that specific addiction-related behaviors are associated with specific genes. 
Herein, I created a phenotype from the ALIVE dataset: injection years. I believe that this 
phenotype is genetically influenced. Therefore, I used it in a genome wide association 
analysis. With the findings from the genome wide association analysis, I conducted a 
polygenic risk score analysis and a pathway analysis.  
5.2 Summary of findings 
Review of Chapter 2. The purpose of this critical review was to find articles to 
provide an answer to the question: Is this phenotype, injection years, at least partly 
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influenced by genetic factors? To that end, I reviewed articles related to injection of 
illegal drugs, addiction, and the genetic evidence for opioid addiction. First, I reviewed 
the literature on substance use disorders and HIV. Injection drug use is a common form 
of administration among opiate dependent individuals, and the use of injectable drugs 
increases the risk of HIV. (Friedland & Klein, 1987) In other words, injection drug users 
are at high risk for HIV, with heroin the most commonly injected drug. Second, I 
reviewed the literature on symptoms and signs of substance use disorder. DSM-IV states 
that the persistent use of a substance can induce changes in brain circuitry and cause 
specific behavior patterns such as craving. (American Psychiatric Association, 2000) 
These findings suggested that substance use disorders are chronic and recurrent, and a 
substance dependent individual’s behavior will change over time. Third, I reviewed the 
literature on the genetic epidemiology of substance use disorders. Tsuang’s twin study, 
Gelernter’s genome wide linkage study and genome wide associations study provided 
ample evidence that genetic factors influence opioid addiction. (Gelernter et al., 2014; 
Gelernter et al., 2006; Tsuang et al., 1998) I created a risk phenotype, injection years to 
evaluate the intensity of injection behavior. Because there is a genetic basis for opioid 
addiction, I am confident that injection years which is highly associated with addiction, is 
also associated with genetics.  
Study in Chapter 3. The purpose of this study was to deal with the missing data in 
a longitudinal cohort and create a risk phenotype, injection year, for the genome wide 
analysis. The ALIVE GWAS subset included 1,197 participants drawn from the ALIVE 
cohort in 1998. They visited semiannually with an average of 19 visits per person. The 
population was predominantly African-American (98%). The mean age of first injection 
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was 21. The mean age at entering was 34. This age difference presented a problem since 
so much data was not available. Sixty-six percent of the recordable visits were missing. I 
imputed the ALIVE GWAS subset with three models: universal, two-predictors, and one-
predictor. Respectively, the mean of the summary of injection years was 23, 19, and 18 
years in universal, two-predictors, and one-predictor models. The mean of the summary 
of injection years in the universal model was much greater than that of the other two 
models. After conducting a sensitivity exam, I chose the universal model for the 
subsequent analysis. I compared the findings in this study with Genberg’s, and the most 
important finding, that the mean injection years were 24, is consistent with hers. 
(Genberg et al., 2011) 
Study in chapter 4. The purpose of this study was to examine the associations 
between injection years and genetic factors by using genome wide association analysis, 
polygenic risk score analysis and pathway analysis. Using PLINK, 735,081 variants and 
1107 people passed filters and quality control. Phenotype data is quantitative. Using 
regression analysis, I tested the SNP associations after adjusting for ancestry components 
and found no single SNP in the GWAS reached the level of genome-wide significance. (p 
< 5 × 10−8) Eleven SNPs exceeded the p < 5 × 10−5 threshold, including one SNP 
(rs10168062) with a p < 5 × 10−7. Using polygenic risk score analysis, I used the ALIVE 
GWAS male group for the discovery sample, considering the four most informative PT 
thresholds from the intra- ALIVE GWAS male group analyses. The highest correlation 
coefficient is around 0.10 when PT is 0.01. The ALIVE GWAS subset supports a 
polygenic basis to injection years that involves many common SNPs. I used INRICH for 
pathway analysis. The 31 intervals were selected for the pathway analysis but none of the 
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gene sets was statistically significant. Two of the top gene sets are 
metallocarboxypeptidase activity and DNA dealkylation involved in DNA repair.  
5.3 Discussion of findings  
In this dissertation, I created a risk phenotype which can be used to represent the 
intensity of injection behavior; and examined the associations between genetics and this 
risk phenotype. The literature supports the proposition that a) injection drug users are at 
high risk for HIV, with heroin the most commonly injected drug, b) substance use 
disorders are chronic and recurrent, and an addict’s behaviors changes with time, c) 
genetic factors influence opioid addiction. Thus, there is a high possibility that injection 
year is associated with genetics. Assuming that multiple genes with small effects 
contribute to injection years, I performed a polygenic risk score analysis and pathway 
analysis in an attempt to ascertain which biological pathways are related to this variable.  
Substance use disorders are chronic and recurrent. Changes in behavior patterns 
occur in individuals with substance abuse disorders; observing these changes over the 
long term can perhaps help us to understand more about the outcomes of addiction. In the 
ALIVE cohort, Genberg et al. found that injection drug users can be categorized into five 
groups with unique trajectories. (Genberg et al., 2011) From Genberg’s findings, I 
believe that measuring the length of time someone has injected drugs can be used to 
evaluate the intensity of injection behavior. However, it is virtually impossible to track 
and collect data from this highly unstable population for any length of time, much less the 
amounts of time required for this study. The longer the study, the higher the amounts of 
missing information. In the ALIVE GWAS subset, subjects had been tracked for a mean 
of approximately ten years; thus, there are vast amounts of missing data. In studying 
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injection drug users, we borrowed the concept of “smoking pack-year” and created a 
phenotype, injection years, to track changes in the status of injected drug use in our 
longitudinal dataset. 
It was necessary to account for the massive amount of missing data before starting 
the analysis. To manage this problem, I imputed injection data in the ALIVE GWAS 
subset with three models: universal, two predictors, and one predictor. In the universal 
model, I supposed that several causal factors continuously influence injection behavior in 
all phases. In the two-predictor model, I supposed that causal factors which influence 
injection behavior change in different phases but may remain the same in the identical 
phase. In the one-predictor model, I used only the existing report, six months prior, as a 
predictor, so the imputed reports were only influenced by the existing reports at the 
identical time point. The results of the sensitivity test supported the use of the universal 
model. With the universal model, the mean of the sum of imputed injection years is 
consistent with the results of Genberg’s study. (Genberg et al., 2011) The findings of this 
study support the use of multiple imputation in a longitudinal cohort such as the ALIVE 
GWAS subset. Clearly, the missing data presents a major obstacle for conducting 
longitudinal studies; multiple imputation using a specific model may provide a solution to 
this problem.  
 In this study, I tested the association between longitudinal addiction behavior and 
genetics. Longitudinal studies are rare in the field of addiction; missing data is a common 
problem in such studies. Using multiple imputation, I created a risk phenotype, injection 
year, which was used in the genome wide association analysis. However, no single SNP 
in the GWAS reached the level of genome-wide significance. This result suggested that 
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injection years might be affected by polygenes and/or gene-gene interactions and/or 
gene-environment interactions, instead of a single gene. Traditional genome wide 
association studies can identify a large portion of genetic risk for diseases but cannot 
detect genetic subsets in which each gene has a very small size effect. Polygenic risk 
score analysis and pathway analysis are used to detect such genetic subsets, using the 
results from genome wide association analysis. In this study, the findings of polygenic 
risk scores analysis support the idea that injection year is influenced by polygenes. No 
significant result was found in pathway analysis. The top two gene sets,  
metallocarboxypeptidase activity and DNA dealkylation, are both involved in DNA 
repair. This result suggests that DNA repair may play a role in our risk phenotype, 
injection year. Linking injection years to genetics, this study offers a practical method for 
exploring genetic influences on specific behavior traits in a longitudinal cohort. I believe 
that two types of studies would be beneficial follow up studies: studies of genetic 
influences on behavioral phenotypes, and studies of genetic influences on longitudinal 
phenotypes. 
5.4 Implications for public health  
Substance use disorders are a major public health issue. Illicit psychoactive drugs 
are associated with a variety of psychological and physical problems. From a public 
health perspective, in the U.S. there are enormous societal consequences to the use of 
illicit drugs. (Birnbaum et al., 2011) These include costs to the health care, law 
enforcement, and criminal justice systems as well as losses workplace productivity of up 
to $50 billion annually. (Birnbaum et al., 2011; Hansen et al., 2011) From a personal 
health perspective, injection drug use leads to a host of physical problems, one of the 
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most serious being the high risk of acquiring HIV. (Friedland & Klein, 1987) There have 
been few studies of injection drug users; it is hoped that this study can be of benefit to 
this group and to those working on all fronts to help them. 
Since treatment for injection drug use comes with no guarantee of success, 
prevention is the preferred strategy. From a public health perspective, disease prevention 
can be categorized as primary, secondary, and tertiary prevention. Secondary prevention 
aims to reduce the impact of a disease or injury that has already occurred. In this 
dissertation, I created a risk phenotype which can be used to measure the intensity of 
injection behavior. I believe injection years can be used to identify those who have 
injected drugs persistently, and who are therefore at highest risk of HIV infection. In 
order to find biological evidence, I tested association between injection and genetics.  
The findings suggest that injection year is influenced by polygenes, and probably by 
gene-gene interactions and gene-environment interaction.  
5.5 Limitations of the studies 
The analyses that are the basis for this dissertation had a number of limitations. 
There are two limitations resulting from multiple imputation analysis. The first was the 
amount of missing data in the ALIVE GWAS subset. Overall, 66 percent of the data is 
missing. The accuracy of imputation is associated with the amount of existing data. These 
amounts of missing data definitely decrease the accuracy of imputation. Another 
limitation was the definition of “injection years.” The definition only describes the 
number of years the person has been injecting; the definition does not take into account 
other aspects like dosage or injection counts. I maintain that the study target, the 
trajectory of injection behavior, is mostly influenced by injection years; however, I 
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cannot exclude the possibility that the target is also influenced by these other factors. 
There were two limitations in the genome wide analyses. First, I did not include the 
variable related to gene-environment interactions because, in a longitudinal study such as 
the ALIVE GWAS cohort, it is hard to define an environmental variable. Although our 
target is the trait of injection behavior which is affected by genetic factors, we cannot 
disentangle the interactions between genetic factors and environmental factors. Second, 
there were fewer than 1,200 subjects. Because there are so few studies of injection drug 
users, we could not find another independent sample to serves as a discovery sample in 
the polygenic risk score analysis. We divided the ALIVE GWAS subset into male and 
female groups, but the number of people in each group was insufficient for polygenic risk 
score analysis. 
5.6 Conclusions and future directions for research 
In this dissertation, I reviewed literature on addiction, HIV risk behaviors and 
genetics to build a solid foundation for my hypothesis. I created a risk phenotype, 
injection years, to examine the sensitivity of different imputation models. The mean of 
imputed injection years were consistent with Genberg’s findings. (Genberg et al., 2011) 
Thus, it could potentially be used as a simple and clear tool to measure the intensity of 
injection behavior. Using the imputed results, I conducted genome wide analyses: 
genome wide association analysis, polygenic risk score analysis, and pathway analysis. 
The findings link genetics to injection years. In brief, I recommend using behavioral 
phenotypes for genome wide analysis to link genetic studies to observable behaviors; I 
believe that this method can provide valuable information about how genetic factors 
influence behavior through specific biological mechanisms. Another potential area for 
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future studies is to analyze longitudinal information to serve as risk phenotype for 
genome wide analysis. 
Longitudinal data can provide information about changes in people’s lives and 
behavior patterns; however, missing data is a major problem. I recommend using multiple 
imputation in other longitudinal studies and selecting an appropriate model by examining 
the accuracy and reliability of the imputed data. By using the appropriate model, I believe 
that reliable imputed records can be obtained from the existing data. Another potential 
area for future studies is to impute a continuous variable such as the injection counts. 
Caporaso et al. used the concept of “smoking pack-year,”  defined as the number of packs 
smoked in a year.(Caporaso et al., 2009) In this study, we did not deal with the issue of 
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